KR20230022514A - Cosmetic composition comprising probiotics cultivatied using dogo hot spring water - Google Patents
Cosmetic composition comprising probiotics cultivatied using dogo hot spring water Download PDFInfo
- Publication number
- KR20230022514A KR20230022514A KR1020210104376A KR20210104376A KR20230022514A KR 20230022514 A KR20230022514 A KR 20230022514A KR 1020210104376 A KR1020210104376 A KR 1020210104376A KR 20210104376 A KR20210104376 A KR 20210104376A KR 20230022514 A KR20230022514 A KR 20230022514A
- Authority
- KR
- South Korea
- Prior art keywords
- hot spring
- dogo
- spring water
- lactobacillus
- cosmetic composition
- Prior art date
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 117
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 239000002537 cosmetic Substances 0.000 title claims abstract description 60
- 239000006041 probiotic Substances 0.000 title description 12
- 235000018291 probiotics Nutrition 0.000 title description 12
- 230000002087 whitening effect Effects 0.000 claims abstract description 15
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 241000186660 Lactobacillus Species 0.000 claims abstract description 7
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 7
- 239000000284 extract Substances 0.000 claims description 67
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 30
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 30
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 30
- 241001608472 Bifidobacterium longum Species 0.000 claims description 25
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 25
- 230000037303 wrinkles Effects 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 230000006872 improvement Effects 0.000 claims description 14
- 239000012676 herbal extract Substances 0.000 claims description 9
- 239000011734 sodium Substances 0.000 claims description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 241000186612 Lactobacillus sakei Species 0.000 claims description 6
- 239000011575 calcium Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 5
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 3
- 241000186012 Bifidobacterium breve Species 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 3
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 3
- 240000001929 Lactobacillus brevis Species 0.000 claims description 3
- 235000013957 Lactobacillus brevis Nutrition 0.000 claims description 3
- 244000199866 Lactobacillus casei Species 0.000 claims description 3
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 3
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 3
- 241000925032 Lactobacillus harbinensis Species 0.000 claims description 3
- 241000186684 Lactobacillus pentosus Species 0.000 claims description 3
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 3
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 3
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 3
- 229940017800 lactobacillus casei Drugs 0.000 claims description 3
- 229940012969 lactobacillus fermentum Drugs 0.000 claims description 3
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 3
- 229910052744 lithium Inorganic materials 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 239000010703 silicon Substances 0.000 claims description 3
- 229910052710 silicon Inorganic materials 0.000 claims description 3
- 229910052712 strontium Inorganic materials 0.000 claims description 3
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 22
- 238000004519 manufacturing process Methods 0.000 abstract description 20
- 102000003425 Tyrosinase Human genes 0.000 abstract description 13
- 108060008724 Tyrosinase Proteins 0.000 abstract description 13
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 abstract description 10
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 abstract description 10
- 230000008099 melanin synthesis Effects 0.000 abstract description 10
- 230000037319 collagen production Effects 0.000 abstract description 6
- 230000037331 wrinkle reduction Effects 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 124
- 238000002360 preparation method Methods 0.000 description 53
- 210000003491 skin Anatomy 0.000 description 48
- 241000411851 herbal medicine Species 0.000 description 43
- 210000004027 cell Anatomy 0.000 description 33
- 239000002609 medium Substances 0.000 description 32
- -1 and accordingly Substances 0.000 description 23
- 230000002401 inhibitory effect Effects 0.000 description 19
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 18
- 239000003921 oil Substances 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 239000000306 component Substances 0.000 description 15
- 238000009472 formulation Methods 0.000 description 15
- 235000019198 oils Nutrition 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- 108010035532 Collagen Proteins 0.000 description 12
- 102000008186 Collagen Human genes 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 12
- 229920001436 collagen Polymers 0.000 description 11
- 239000002131 composite material Substances 0.000 description 11
- 239000006210 lotion Substances 0.000 description 11
- 238000002835 absorbance Methods 0.000 description 9
- 238000000855 fermentation Methods 0.000 description 9
- 230000004151 fermentation Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
- 239000006071 cream Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 230000032683 aging Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 229940088594 vitamin Drugs 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- 235000013343 vitamin Nutrition 0.000 description 7
- 239000011782 vitamin Substances 0.000 description 7
- 241001474374 Blennius Species 0.000 description 6
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000003205 fragrance Substances 0.000 description 6
- 210000002752 melanocyte Anatomy 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 5
- 239000004909 Moisturizer Substances 0.000 description 5
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 5
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 5
- 239000003086 colorant Substances 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000001333 moisturizer Effects 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000037394 skin elasticity Effects 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- SNPLKNRPJHDVJA-UHFFFAOYSA-N dl-panthenol Chemical compound OCC(C)(C)C(O)C(=O)NCCCO SNPLKNRPJHDVJA-UHFFFAOYSA-N 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 4
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 229960004063 propylene glycol Drugs 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- OBETXYAYXDNJHR-UHFFFAOYSA-N 2-Ethylhexanoic acid Chemical compound CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 3
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 206010014970 Ephelides Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 3
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 3
- 208000003351 Melanosis Diseases 0.000 description 3
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 108010050808 Procollagen Proteins 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Natural products OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229960000458 allantoin Drugs 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- SHZIWNPUGXLXDT-UHFFFAOYSA-N caproic acid ethyl ester Natural products CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 229940072106 hydroxystearate Drugs 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 239000010466 nut oil Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 229920002545 silicone oil Polymers 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 150000003408 sphingolipids Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 description 2
- DHGBAFGZLVRESL-UHFFFAOYSA-N 14-methylpentadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C DHGBAFGZLVRESL-UHFFFAOYSA-N 0.000 description 2
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 2
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- BMFMQGXDDJALKQ-BYPYZUCNSA-N Argininic acid Chemical compound NC(N)=NCCC[C@H](O)C(O)=O BMFMQGXDDJALKQ-BYPYZUCNSA-N 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 108010075254 C-Peptide Proteins 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 description 2
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 206010051246 Photodermatosis Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 230000001153 anti-wrinkle effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 229940079894 benzophenone-9 Drugs 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- RAPXDXJBAYUBHI-UHFFFAOYSA-N decyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCCCCCC RAPXDXJBAYUBHI-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- WPUMTJGUQUYPIV-JIZZDEOASA-L disodium (S)-malate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)CC([O-])=O WPUMTJGUQUYPIV-JIZZDEOASA-L 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- QDCHWIWENYCPIL-UHFFFAOYSA-L disodium;4-hydroxy-5-(2-hydroxy-4-methoxy-5-sulfonatobenzoyl)-2-methoxybenzenesulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC(S([O-])(=O)=O)=C(OC)C=C1O QDCHWIWENYCPIL-UHFFFAOYSA-L 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- MVLVMROFTAUDAG-UHFFFAOYSA-N ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC MVLVMROFTAUDAG-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940060384 isostearyl isostearate Drugs 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 210000002780 melanosome Anatomy 0.000 description 2
- 238000009629 microbiological culture Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000019488 nut oil Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- OQILCOQZDHPEAZ-UHFFFAOYSA-N octyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- AFDXODALSZRGIH-UHFFFAOYSA-N p-coumaric acid methyl ether Natural products COC1=CC=C(C=CC(O)=O)C=C1 AFDXODALSZRGIH-UHFFFAOYSA-N 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000008845 photoaging Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 230000036560 skin regeneration Effects 0.000 description 2
- 235000019265 sodium DL-malate Nutrition 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000011083 sodium citrates Nutrition 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- 239000001394 sodium malate Substances 0.000 description 2
- 229940074404 sodium succinate Drugs 0.000 description 2
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 2
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- DEQUKPCANKRTPZ-UHFFFAOYSA-N (2,3-dihydroxyphenyl)-phenylmethanone Chemical compound OC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1O DEQUKPCANKRTPZ-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- CSTRPYAGFNTOEQ-MGMRMFRLSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;octadecanoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCCCC(O)=O CSTRPYAGFNTOEQ-MGMRMFRLSA-N 0.000 description 1
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- BJDAUCLANVMIOB-UHFFFAOYSA-N (3-decanoyloxy-2,2-dimethylpropyl) decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)(C)COC(=O)CCCCCCCCC BJDAUCLANVMIOB-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical compound CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 description 1
- GLXBPZNFNSLJBS-UHFFFAOYSA-N 11-methyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCCCCCCCCC(C)C GLXBPZNFNSLJBS-UHFFFAOYSA-N 0.000 description 1
- 229940114072 12-hydroxystearic acid Drugs 0.000 description 1
- OUZOBPPZPCBJAR-UHFFFAOYSA-N 14-methylpentadecyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C OUZOBPPZPCBJAR-UHFFFAOYSA-N 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- YICVJSOYNBZJAK-UHFFFAOYSA-N 14-methylpentadecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C YICVJSOYNBZJAK-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- SAMYFBLRCRWESN-UHFFFAOYSA-N 16-methylheptadecyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC(C)C SAMYFBLRCRWESN-UHFFFAOYSA-N 0.000 description 1
- MVUWRLHKGKEGSS-UHFFFAOYSA-N 16-methylheptadecyl octanoate Chemical compound CCCCCCCC(=O)OCCCCCCCCCCCCCCCC(C)C MVUWRLHKGKEGSS-UHFFFAOYSA-N 0.000 description 1
- VRBHTEGUHVNKEA-UHFFFAOYSA-N 16-methylheptadecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC(C)C VRBHTEGUHVNKEA-UHFFFAOYSA-N 0.000 description 1
- RKJGFHYCZPZJPE-UHFFFAOYSA-N 2,2-bis(16-methylheptadecanoyloxymethyl)butyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(CC)(COC(=O)CCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCC(C)C RKJGFHYCZPZJPE-UHFFFAOYSA-N 0.000 description 1
- FUTGDWNFCMWSJT-UHFFFAOYSA-N 2,3-bis(14-methylpentadecanoyloxy)propyl 14-methylpentadecanoate Chemical compound CC(C)CCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCC(C)C FUTGDWNFCMWSJT-UHFFFAOYSA-N 0.000 description 1
- JNAYPSWVMNJOPQ-UHFFFAOYSA-N 2,3-bis(16-methylheptadecanoyloxy)propyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCC(C)C JNAYPSWVMNJOPQ-UHFFFAOYSA-N 0.000 description 1
- XFOQWQKDSMIPHT-UHFFFAOYSA-N 2,3-dichloro-6-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Cl)C(Cl)=N1 XFOQWQKDSMIPHT-UHFFFAOYSA-N 0.000 description 1
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-Hydroxyoctadecanoic acid Natural products CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 description 1
- NFIHXTUNNGIYRF-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCC NFIHXTUNNGIYRF-UHFFFAOYSA-N 0.000 description 1
- JGUMTYWKIBJSTN-UHFFFAOYSA-N 2-ethylhexyl 4-[[4,6-bis[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 JGUMTYWKIBJSTN-UHFFFAOYSA-N 0.000 description 1
- LEEDMQGKBNGPDN-UHFFFAOYSA-N 2-methylnonadecane Chemical compound CCCCCCCCCCCCCCCCCC(C)C LEEDMQGKBNGPDN-UHFFFAOYSA-N 0.000 description 1
- HTNFLUQQANUSLR-UHFFFAOYSA-N 2-octanoyloxyethyl octanoate Chemical compound CCCCCCCC(=O)OCCOC(=O)CCCCCCC HTNFLUQQANUSLR-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- GECRRQVLQHRVNH-MRCUWXFGSA-N 2-octyldodecyl (z)-octadec-9-enoate Chemical compound CCCCCCCCCCC(CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC GECRRQVLQHRVNH-MRCUWXFGSA-N 0.000 description 1
- PTPDZZWUOHQSLG-UHFFFAOYSA-N 2-octyldodecyl 2,2-dimethylpropanoate Chemical compound CCCCCCCCCCC(COC(=O)C(C)(C)C)CCCCCCCC PTPDZZWUOHQSLG-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- YPIFGDQKSSMYHQ-UHFFFAOYSA-M 7,7-dimethyloctanoate Chemical compound CC(C)(C)CCCCCC([O-])=O YPIFGDQKSSMYHQ-UHFFFAOYSA-M 0.000 description 1
- ODMZDMMTKHXXKA-QXMHVHEDSA-N 8-methylnonyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCCCCCCC(C)C ODMZDMMTKHXXKA-QXMHVHEDSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- 241000219227 Acer japonicum Species 0.000 description 1
- 241000219231 Acer pseudosieboldianum Species 0.000 description 1
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 235000006667 Aleurites moluccana Nutrition 0.000 description 1
- 244000136475 Aleurites moluccana Species 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- ZCTQGTTXIYCGGC-UHFFFAOYSA-N Benzyl salicylate Chemical group OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 ZCTQGTTXIYCGGC-UHFFFAOYSA-N 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- RDOFJDLLWVCMRU-UHFFFAOYSA-N Diisobutyl adipate Chemical compound CC(C)COC(=O)CCCCC(=O)OCC(C)C RDOFJDLLWVCMRU-UHFFFAOYSA-N 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 241000576429 Forsythia suspensa Species 0.000 description 1
- 241001198934 Forsythia viridissima Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- ZWQVYZXPYSYPJD-RYUDHWBXSA-N Glu-Gly-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZWQVYZXPYSYPJD-RYUDHWBXSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- GWFGDXZQZYMSMJ-UHFFFAOYSA-N Octadecansaeure-heptadecylester Natural products CCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC GWFGDXZQZYMSMJ-UHFFFAOYSA-N 0.000 description 1
- RJECHNNFRHZQKU-UHFFFAOYSA-N Oelsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCCCCCCCC)C2 RJECHNNFRHZQKU-UHFFFAOYSA-N 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 240000005001 Paeonia suffruticosa Species 0.000 description 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 1
- 241001106477 Paeoniaceae Species 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- NKSOSPOXQKNIKJ-CLFAGFIQSA-N Polyoxyethylene dioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCOC(=O)CCCCCCC\C=C/CCCCCCCC NKSOSPOXQKNIKJ-CLFAGFIQSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010040865 Skin hyperpigmentation Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010059516 Skin toxicity Diseases 0.000 description 1
- 244000197975 Solidago virgaurea Species 0.000 description 1
- 235000000914 Solidago virgaurea Nutrition 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- PRLUQOOFPFWUKQ-KKTNLPSRSA-N [(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl] (z)-octadec-9-enoate Chemical compound C1C[C@@H]2[C@@]3(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C[C@@H]3CC[C@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@]21C PRLUQOOFPFWUKQ-KKTNLPSRSA-N 0.000 description 1
- XKMYWNHZAQUEPY-YZGJEOKZSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 12-hydroxyoctadecanoate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCC(O)CCCCCC)C1 XKMYWNHZAQUEPY-YZGJEOKZSA-N 0.000 description 1
- WUBKCBOQNXUQDU-UHFFFAOYSA-N [2-(dihydroxymethoxy)phenyl]-phenylmethanone Chemical compound OC(O)OC1=CC=CC=C1C(=O)C1=CC=CC=C1 WUBKCBOQNXUQDU-UHFFFAOYSA-N 0.000 description 1
- SVRHJWALMLOXMI-UHFFFAOYSA-N [2-(dihydroxymethoxy)phenyl]-phenylmethanone;sodium Chemical compound [Na].OC(O)OC1=CC=CC=C1C(=O)C1=CC=CC=C1 SVRHJWALMLOXMI-UHFFFAOYSA-N 0.000 description 1
- YRXGUZPUZBCGST-UHFFFAOYSA-N [2-(hydroxymethoxy)phenyl]-phenylmethanone Chemical compound OCOC1=CC=CC=C1C(=O)C1=CC=CC=C1 YRXGUZPUZBCGST-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000010477 apricot oil Substances 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000001518 benzyl (E)-3-phenylprop-2-enoate Substances 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- NGHOLYJTSCBCGC-QXMHVHEDSA-N benzyl cinnamate Chemical compound C=1C=CC=CC=1\C=C/C(=O)OCC1=CC=CC=C1 NGHOLYJTSCBCGC-QXMHVHEDSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- HGKOWIQVWAQWDS-UHFFFAOYSA-N bis(16-methylheptadecyl) 2-hydroxybutanedioate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CC(O)C(=O)OCCCCCCCCCCCCCCCC(C)C HGKOWIQVWAQWDS-UHFFFAOYSA-N 0.000 description 1
- WMNULTDOANGXRT-UHFFFAOYSA-N bis(2-ethylhexyl) butanedioate Chemical compound CCCCC(CC)COC(=O)CCC(=O)OCC(CC)CCCC WMNULTDOANGXRT-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- DHAZIUXMHRHVMP-UHFFFAOYSA-N butyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCC DHAZIUXMHRHVMP-UHFFFAOYSA-N 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- XHRPOTDGOASDJS-UHFFFAOYSA-N cholesterol n-octadecanoate Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCCCCCCCCCCC)C2 XHRPOTDGOASDJS-UHFFFAOYSA-N 0.000 description 1
- 229940072104 cholesteryl hydroxystearate Drugs 0.000 description 1
- RJECHNNFRHZQKU-RMUVNZEASA-N cholesteryl oleate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C1 RJECHNNFRHZQKU-RMUVNZEASA-N 0.000 description 1
- XHRPOTDGOASDJS-XNTGVSEISA-N cholesteryl stearate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)C1 XHRPOTDGOASDJS-XNTGVSEISA-N 0.000 description 1
- NGHOLYJTSCBCGC-UHFFFAOYSA-N cis-cinnamic acid benzyl ester Natural products C=1C=CC=CC=1C=CC(=O)OCC1=CC=CC=C1 NGHOLYJTSCBCGC-UHFFFAOYSA-N 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- BOUIEBMBWBCUPB-UHFFFAOYSA-N decyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCCCCCCCC BOUIEBMBWBCUPB-UHFFFAOYSA-N 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940031769 diisobutyl adipate Drugs 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 229940031569 diisopropyl sebacate Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- MIMDHDXOBDPUQW-UHFFFAOYSA-N dioctyl decanedioate Chemical compound CCCCCCCCOC(=O)CCCCCCCCC(=O)OCCCCCCCC MIMDHDXOBDPUQW-UHFFFAOYSA-N 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- XFKBBSZEQRFVSL-UHFFFAOYSA-N dipropan-2-yl decanedioate Chemical compound CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C XFKBBSZEQRFVSL-UHFFFAOYSA-N 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- QQQMUBLXDAFBRH-UHFFFAOYSA-N dodecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)O QQQMUBLXDAFBRH-UHFFFAOYSA-N 0.000 description 1
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- MCPKSFINULVDNX-UHFFFAOYSA-N drometrizole Chemical compound CC1=CC=C(O)C(N2N=C3C=CC=CC3=N2)=C1 MCPKSFINULVDNX-UHFFFAOYSA-N 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- HPMLGOFBKNGJAM-ONEGZZNKSA-N ethyl (e)-3-(1h-imidazol-5-yl)prop-2-enoate Chemical compound CCOC(=O)\C=C\C1=CN=CN1 HPMLGOFBKNGJAM-ONEGZZNKSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 description 1
- 229940031016 ethyl linoleate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000010196 hermaphroditism Effects 0.000 description 1
- DWMMZQMXUWUJME-UHFFFAOYSA-N hexadecyl octanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC DWMMZQMXUWUJME-UHFFFAOYSA-N 0.000 description 1
- QAKXLTNAJLFSQC-UHFFFAOYSA-N hexadecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC QAKXLTNAJLFSQC-UHFFFAOYSA-N 0.000 description 1
- FPMPNVIMFPEKRN-UHFFFAOYSA-N hexyl 16-methylheptadecanoate Chemical compound CCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C FPMPNVIMFPEKRN-UHFFFAOYSA-N 0.000 description 1
- 229940100463 hexyl laurate Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940078568 isocetyl myristate Drugs 0.000 description 1
- 229940078545 isocetyl stearate Drugs 0.000 description 1
- 229940093629 isopropyl isostearate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940113915 isostearyl palmitate Drugs 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 231100000544 menstrual irregularity Toxicity 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- LAQFLZHBVPULPL-UHFFFAOYSA-N methyl(phenyl)silicon Chemical compound C[Si]C1=CC=CC=C1 LAQFLZHBVPULPL-UHFFFAOYSA-N 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- VAMFXQBUQXONLZ-UHFFFAOYSA-N n-alpha-eicosene Natural products CCCCCCCCCCCCCCCCCCC=C VAMFXQBUQXONLZ-UHFFFAOYSA-N 0.000 description 1
- GQEZCXVZFLOKMC-UHFFFAOYSA-N n-alpha-hexadecene Natural products CCCCCCCCCCCCCCC=C GQEZCXVZFLOKMC-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- NKBWPOSQERPBFI-UHFFFAOYSA-N octadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC NKBWPOSQERPBFI-UHFFFAOYSA-N 0.000 description 1
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
- WCJLCOAEJIHPCW-UHFFFAOYSA-N octyl 2-hydroxybenzoate Chemical group CCCCCCCCOC(=O)C1=CC=CC=C1O WCJLCOAEJIHPCW-UHFFFAOYSA-N 0.000 description 1
- YPMOZWCBANATQH-UHFFFAOYSA-N octyl 7-methyloctanoate Chemical compound CCCCCCCCOC(=O)CCCCCC(C)C YPMOZWCBANATQH-UHFFFAOYSA-N 0.000 description 1
- IIGMITQLXAGZTL-UHFFFAOYSA-N octyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCC IIGMITQLXAGZTL-UHFFFAOYSA-N 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 229940048862 octyldodecyl neopentanoate Drugs 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000010702 perfluoropolyether Substances 0.000 description 1
- ZQBAKBUEJOMQEX-UHFFFAOYSA-N phenyl salicylate Chemical group OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 ZQBAKBUEJOMQEX-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- LYKRPDCJKSXAHS-UHFFFAOYSA-N phenyl-(2,3,4,5-tetrahydroxyphenyl)methanone Chemical compound OC1=C(O)C(O)=CC(C(=O)C=2C=CC=CC=2)=C1O LYKRPDCJKSXAHS-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 description 1
- 229940033329 phytosphingosine Drugs 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 235000010408 potassium alginate Nutrition 0.000 description 1
- 239000000737 potassium alginate Substances 0.000 description 1
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- XEIOPEQGDSYOIH-MURFETPASA-N propan-2-yl (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC(C)C XEIOPEQGDSYOIH-MURFETPASA-N 0.000 description 1
- NEOZOXKVMDBOSG-UHFFFAOYSA-N propan-2-yl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC(C)C NEOZOXKVMDBOSG-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229940116422 propylene glycol dicaprate Drugs 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 231100000438 skin toxicity Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- BORJONZPSTVSFP-UHFFFAOYSA-N tetradecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(C)O BORJONZPSTVSFP-UHFFFAOYSA-N 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
- LOIYMIARKYCTBW-UHFFFAOYSA-N trans-urocanic acid Natural products OC(=O)C=CC1=CNC=N1 LOIYMIARKYCTBW-UHFFFAOYSA-N 0.000 description 1
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 229940118594 trimethylolpropane triisostearate Drugs 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- APVVRLGIFCYZHJ-UHFFFAOYSA-N trioctyl 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CCCCCCCCOC(=O)CC(O)(C(=O)OCCCCCCCC)CC(=O)OCCCCCCCC APVVRLGIFCYZHJ-UHFFFAOYSA-N 0.000 description 1
- COXJMKGEQAWXNP-UHFFFAOYSA-N tris(14-methylpentadecyl) 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CC(C)CCCCCCCCCCCCCOC(=O)CC(O)(C(=O)OCCCCCCCCCCCCCC(C)C)CC(=O)OCCCCCCCCCCCCCC(C)C COXJMKGEQAWXNP-UHFFFAOYSA-N 0.000 description 1
- RHNXTZDKMRCKKT-UHFFFAOYSA-N tris(6-methylheptyl) 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CC(C)CCCCCOC(=O)CC(O)(C(=O)OCCCCCC(C)C)CC(=O)OCCCCCC(C)C RHNXTZDKMRCKKT-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 238000003911 water pollution Methods 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/965—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of inanimate origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Inorganic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 도고온천수를 이용하여 배양된 프로바이오틱스를 포함하는 화장료 조성물에 관한 것으로, 더욱 상세하게는 도고온천수와 한약재를 포함하는 배지에서 배양된 프로바이오틱스를 포함하는 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition containing probiotics cultured using Dogo hot spring water, and more particularly, to a cosmetic composition containing probiotics cultured in a medium containing Dogo hot spring water and herbal medicines.
피부는 신체 중 가장 큰 기관으로 항상 외부환경과 직접 접하고 있으면서 여러가지 자극이나 건조한 환경으로부터 생체를 보호하는 보호막의 역할을 하고 있으며, 다른 기관에 비하여 새로운 세포의 생성과 소멸이 활발히 일어난다. 또한, 물리적인 찰과상으로부터 신체를 보호하고, 신체 내부의 수분 손실을 막아주며 태양에서 발생되는 자외선으로부터 보호해줄 뿐만 아니라, 몸의 체온을 조절해주는 매우 중요한 역할을 담당하고 있다.The skin is the largest organ in the body and always directly in contact with the external environment, playing the role of a protective film to protect the living body from various stimuli or dry environments. In addition, it protects the body from physical abrasions, prevents loss of moisture inside the body, protects from ultraviolet rays generated by the sun, and plays a very important role in regulating the body temperature.
이러한 피부는 여러 가지 물리적 요인, 외부환경적 요인, 감염 등으로 인해 피부의 오염과 건조, 트러블, 피부 면역체계 이상 등의 문제가 발생한다. 특히, 현대의 급격한 산업발전에 따라, 대기공해, 수질공해 등의 공해문제가 심각해지고, 주거환경의 개선에 따른 거주공간의 강한 냉난방에 의해 피부의 거칠어짐, 건조, 노화 등과 같이 피부가 외부환경으로부터 큰 영향을 받고 있다. 인간의 피부는 내인성 노화(intrinsic aging)와 광노화에 의해 점차 피부가 얇아지고 주름이 증가하며, 탄력이 감소될 뿐만 아니라 자외선 노출에 의해 기미와 주근깨가 증가하게 된다. 특히, 내인성 노화는 호르몬 분비가 감소하거나 면역세포의 기능과 활성이 저하됨에 따라 생체 구성 단백질들의 생합성이 줄어들면서 발생하는데 이는 활성산소 증가에 따라 급속히 진행된다. Such skin causes problems such as skin contamination, dryness, trouble, skin immune system abnormality, etc. due to various physical factors, external environmental factors, infections, and the like. In particular, with the rapid industrial development of modern times, pollution problems such as air pollution and water pollution have become serious, and the strong cooling and heating of the living space due to the improvement of the residential environment causes the skin to become rough, dry, and aging. are greatly influenced by Human skin gradually becomes thinner due to intrinsic aging and photoaging, wrinkles increase, elasticity decreases, and spots and freckles increase due to exposure to ultraviolet rays. In particular, endogenous aging occurs when the secretion of hormones decreases or the function and activity of immune cells decrease, resulting in a decrease in the biosynthesis of biocomponent proteins, which progresses rapidly with an increase in active oxygen.
인간은 대사과정에서 끊임없이 활성산소종(Reactive Oxygen Species)을 발생시키며 이는 직·간접적인 노화의 원인물질로 작용한다고 알려져 있다. 피부노화를 방지하기 위해 화장품에는 다양한 항산화제가 사용되고 있는데 대표적인 합성 항산화제로 BHT(butylatedhydroxytoluene), BHA(butylated hydroxyanisole)와 tertiary butylhydroquinone(TBHQ) 등이 있다. 일반적으로 합성 항산화제는 우수한 효과와 낮은 가격으로 인해 폭넓게 사용되고 있지만 경구 또는 피부접촉 시 자체 독성뿐만 아니라 간비대증, 지방변이 및 암을 유발하는 것으로 알려져 사용이 제한받고 있다. It is known that humans constantly generate reactive oxygen species in the metabolic process, which act as direct or indirect causes of aging. In order to prevent skin aging, various antioxidants are used in cosmetics, and typical synthetic antioxidants include butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), and tertiary butylhydroquinone (TBHQ). In general, synthetic antioxidants are widely used due to their excellent effects and low prices, but their use is limited because they are known to cause liver enlargement, fatty mutations, and cancer as well as self-toxicity when in oral or skin contact.
미백 기능성 화장품 원료로 이용되는 나이아신아마이드와 알부틴, 그리고 주름 개선 기능성 화장품 원료로 사용되는 레티놀 등은 산화에 의한 성분파괴와 피부 자극 유발로 인한 배합량 제한에 따라 미백 효과가 저하되는 문제가 있다. 최근에는 천연물질을 이용한 다양한 화장료 조성물이 시장에 나오면서 기존에 화학물질로 이루어진 제품들 보다는 천연물질을 이용한 제품에 소비자들이 관심을 가지게 되고, 이에 따라 다양한 천연물질을 이용한 화장료 조성물이 제조되고 있다.Niacinamide and arbutin, which are used as raw materials for whitening functional cosmetics, and retinol, which are used as raw materials for wrinkle-improving functional cosmetics, have a problem in that the whitening effect is reduced due to the destruction of ingredients by oxidation and the restriction of the mixing amount due to skin irritation. Recently, as various cosmetic compositions using natural materials have appeared on the market, consumers have become interested in products using natural materials rather than products made of existing chemical materials, and accordingly, cosmetic compositions using various natural materials are being manufactured.
또한, 화장품에 의한 주름개선 효과는 보습인자들에 의한 보습에 의한 일시적 효과 이외에도 다양한 유효성분들에 의한 진피층 개선 효과를 그 기전으로 하며, 대표적인 주름개선 화장품의 원료들인 레티놀, 비타민C, EGF 등의 성장인자 성분들은 인간 진피 섬유아세포로부터 콜라겐 신생성을 증가시킴으로써 주름 개선 효능을 보이는 것으로 잘 알려져 있다. 이러한 현상을 방지하고 보다 건강하고 아름다운 피부를 유지하기 위해서, 기존에 알려진 각종 동물, 식물, 미생물 등으로부터 얻은 생리 활성 물질들을 화장품에 부가하여 사용함으로써 피부의 고유기능을 유지시키고 피부세포를 활성화시켜 피부노화를 효과적으로 억제시키기 위한 노력이 있어왔다. In addition, the anti-wrinkle effect of cosmetics is based on the effect of improving the dermis layer by various active ingredients in addition to the temporary effect of moisturizing by moisturizing factors, and the growth of retinol, vitamin C, and EGF, which are representative raw materials of wrinkle-improving cosmetics, Factor components are well known to exhibit anti-wrinkle effects by increasing collagen generation from human dermal fibroblasts. In order to prevent this phenomenon and maintain a healthier and more beautiful skin, physiologically active substances obtained from various known animals, plants, microorganisms, etc. are added to cosmetics and used to maintain the unique function of the skin and activate skin cells to Efforts have been made to effectively inhibit aging.
화장품 분야에서는 미백, 주름 개선효과를 갖는 기능성 화장품에 대한 연구 및 개발이 활발하게 진행되고 있으며, 특히 피부에 독성이나 자극을 주지 않기 위하여 천연 물질을 이용한 연구가 계속되고 있다.In the field of cosmetics, research and development on functional cosmetics having whitening and wrinkle-improving effects are being actively conducted, and in particular, studies using natural substances are continuing to avoid toxicity or irritation to the skin.
본 발명의 목적은 도고온천수 및 한약재 추출물을 이용하여 배양된 프로바이오틱스 배양물을 유효성분으로 포함하여 피부 미백 또는 주름 개선 효과가 있는 화장료 조성물을 제공하는 데 있다.An object of the present invention is to provide a cosmetic composition containing, as an active ingredient, a probiotics culture cultured using Dogo hot spring water and an herbal medicine extract, which has a skin whitening or wrinkle improvement effect.
본 발명의 하나의 측면에 따르면,According to one aspect of the invention,
도고온천수를 포함하는 배지에서 배양된 락토바실러스(Lactobacillus) 속 균주를 포함하는 배양물; 및Cultures containing strains of the genus Lactobacillus cultured in a medium containing Dogo hot spring water; and
도고온천수를 포함하는 배지에서 배양된 비피도박테리움(Bifidobacterium) 속 균주를 포함하는 배양물;을 유효성분으로 포함하는 화장료 조성물이 제공된다.A cosmetic composition containing as an active ingredient is provided; a culture containing a strain of the genus Bifidobacterium cultured in a medium containing Dogo hot spring water.
상기 도고온천수를 포함하는 배지는 목단피 추출물, 계조축 추출물 및 연교 추출물 중에서 선택된 1종 이상을 포함하는 한약재 추출물을 추가로 포함할 수 있다.The medium containing the Dogo hot spring water may further include a herbal medicine extract containing at least one selected from the group consisting of mudanpi extract, gyejochuk extract, and yeongyo extract.
상기 한약재 추출물은 물, 탄소수 1-4의 알코올, 또는 이들의 혼합용매에 의해 추출된 것일 수 있다.The herbal medicine extract may be extracted by water, alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
상기 도고온천수를 포함하는 배지는 상기 도고온천수를 10 내지 40 %(v/v) 포함할 수 있다.The medium containing the Dogo hot spring water may contain 10 to 40% (v/v) of the Dogo hot spring water.
상기 도고온천수를 포함하는 배지는 상기 한약재 추출물을 1 내지 5 %(v/v) 포함하고, 상기 한약재 추출물은 고형분 함량이 10 내지 20%(w/v) 일 수 있다.The medium containing the Dogo hot spring water contains 1 to 5% (v/v) of the herbal medicine extract, and the herbal medicine extract may have a solid content of 10 to 20% (w/v).
상기 도고온천수는 칼슘(Ca) 55 내지 65 mg/L, 나트륨(Na) 25 내지 35 mg/L, 실리콘(Si) 10 내지 20 mg/L, 리튬(Li) 0.001 내지 0.05 mg/L 및 스트론튬(Sr) 1.0 내지 2.0 mg/L를 포함할 수 있다.The Dogo hot spring water contains 55 to 65 mg/L of calcium (Ca), 25 to 35 mg/L of sodium (Na), 10 to 20 mg/L of silicon (Si), 0.001 to 0.05 mg/L of lithium (Li) and strontium ( Sr) 1.0 to 2.0 mg/L.
상기 락토바실러스(Lactobacillus) 속 균주는 락토바실러스 플란타룸(Lactobacillus plantarum), 락토바실러스 루테리(Lactobacillus reuteri), 락토바실러스 하비넨시스(Lactobacillus harbinensis), 락토바실러스 카세이(Lactobacillus casei), 락토바실러스 사케이(Lactobacillus sakei), 락토바실러스 브레비스(Lactobacillus brevis), 락토바실러스 펜토서스(Lactobacillus pentosus), 락토바실러스 퍼멘텀(Lactobacillus fermentum), 락토바실러스 애시도필러스(Lactobacillus acidophilus) 및 락토바실러스 람노서스(Lactobacillus rhamnosus) 중에서 선택된 어느 하나일 수 있다.The strains of the genus Lactobacillus include Lactobacillus plantarum , Lactobacillus reuteri , Lactobacillus harbinensis, Lactobacillus casei , Lactobacillus sake ( Among Lactobacillus sakei ), Lactobacillus brevis , Lactobacillus pentosus , Lactobacillus fermentum , Lactobacillus acidophilus and Lactobacillus rhamnosus It can be any one selected.
상기 비피도박테리움(Bifidobacterium) 속 균주는 비피도박테리움 롱검(Bifidobacterium longum), 비피도박테리움 브레베(Bifidobacterium breve), 비피도박테리움 락티스(Bifidobacterium lactis), 및 비피도박테리움 비피덤(Bifidobacterium bifidum) 중에서 선택된 어느 하나일 수 있다.The Bifidobacterium genus strains include Bifidobacterium longum, Bifidobacterium breve , Bifidobacterium lactis, and Bifidobacterium bifidum. ( Bifidobacterium bifidum ) It may be any one selected from.
상기 화장료 조성물은 피부 미백 또는 주름 개선용일 수 있다.The cosmetic composition may be used for skin whitening or wrinkle improvement.
본 발명의 도고온천수를 이용하여 배양된 프로바이오틱스를 포함하는 화장료 조성물은 MMP-1 단백질의 생성을 억제하고 콜라겐 생성을 촉진하며, 티로시나제 억제와 멜라닌 생성 억제능이 있어 피부 미백 및 주름 개선 효과가 우수하다. The cosmetic composition containing probiotics cultured using Dogo hot spring water of the present invention inhibits the production of MMP-1 protein, promotes collagen production, and has the ability to inhibit tyrosinase and melanin production, so it has excellent skin whitening and wrinkle improvement effects.
본 발명은 다양한 변환을 가할 수 있고 여러 가지 실시예를 가질 수 있는 바, 특정 실시예들을 도면에 예시하고 상세한 설명에 상세하게 설명하고자 한다. 그러나, 이는 본 발명을 특정한 실시 형태에 대해 한정하려는 것이 아니며, 본 발명의 사상 및 기술 범위에 포함되는 모든 변환, 균등물 내지 대체물을 포함하는 것으로 이해되어야 한다. 본 발명을 설명함에 있어서 관련된 공지 기술에 대한 구체적인 설명이 본 발명의 요지를 흐릴 수 있다고 판단되는 경우 그 상세한 설명을 생략한다.Since the present invention can apply various transformations and have various embodiments, specific embodiments will be illustrated in the drawings and described in detail in the detailed description. However, it should be understood that this is not intended to limit the present invention to specific embodiments, and includes all transformations, equivalents, and substitutes included in the spirit and scope of the present invention. In describing the present invention, if it is determined that a detailed description of related known technologies may obscure the gist of the present invention, the detailed description will be omitted.
이하, 본 발명의 도고온천수를 이용하여 배양된 프로바이오틱스를 포함하는 화장료 조성물에 대해 설명하도록 한다. Hereinafter, a cosmetic composition containing probiotics cultured using the Dogo hot spring water of the present invention will be described.
본 발명의 화장료 조성물은 도고온천수를 포함하는 배지에서 배양된 락토바실러스(Lactobacillus) 속 균주를 포함하는 배양물; 및 도고온천수를 포함하는 배지에서 배양된 비피도박테리움(Bifidobacterium) 속 균주를 포함하는 배양물;을 유효성분으로 포함하는 것을 특징으로 한다. 상기 배양물에서 배양된 균주는 제거하지 않고 화장료의 유효성분으로 사용하는 것을 특징으로 한다.The cosmetic composition of the present invention is a culture containing a strain of the genus Lactobacillus cultured in a medium containing Dogo hot spring water; And a culture containing a strain of the genus Bifidobacterium cultured in a medium containing Dogo hot spring water; characterized in that it comprises as an active ingredient. The strain cultured in the culture is characterized in that it is used as an active ingredient of cosmetics without being removed.
바람직하게는, 상기 도고온천수를 포함하는 배지는 목단피 추출물, 계조축 추출물 및 연교 추출물 중에서 선택된 1종 이상을 포함하는 한약재 추출물을 추가로 포함할 수 있고, 더욱 바람직하게는 단피 추출물, 계조축 추출물 및 연교 추출물을 포함하는 3종 복합 한약재를 사용할 수 있다. 3종 중 어느 하나를 제외시킬 경우 주름 개선이나 미백 효과가 3종 복합 한약재를 사용하는 경우에 비하여 크게 저하될 수 있다.Preferably, the medium containing the Dogo hot spring water may further include a herbal medicine extract containing at least one selected from mudanpi extract, gyaejochuk extract and yeongyo extract, more preferably danpi extract, gyaejochuk extract and It is possible to use three types of complex herbal medicines containing Yeongyo extract. If any one of the three types is excluded, the wrinkle improvement or whitening effect may be greatly reduced compared to the case of using the three types of compound herbal medicine.
상기 목단피, 계조축, 연교를 포함하는 한약재 추출물은 물, 탄소수 1-4의 알코올, 또는 이들의 혼합용매에 의해 추출된 것일 수 있고, 바람직하게는 열수추출물 일 수 있다.The extract of medicinal herbs including Mokdanpi, Gyejochuk, and Yeongyo may be extracted with water, alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof, preferably a hot water extract.
목단피는 작약과의 모란(Paeonia suffruticosa Andrews)의 뿌리껍질로 만든 약재로서 중국과 일본에서도 우리나라와 동일하게 사용한다. 목단피는 혈열로 인한 생리불순, 생리통, 멍들었을 때, 토혈, 코피, 반점이 나타나는 증상, 허열로 인해 뼛골이 쑤시는 증상, 혈압상승, 어혈제거, 타박상, 소염진통, 종기치료, 맹장염초기 등에 사용하며 가슴답답증을 없애준다고 알려져 있다. 약리작용으로 진통, 진정, 해열, 항경련, 항염증, 항혈전, 항알레르기, 위액분비억제, 자궁점막충혈, 항균작용 등이 보고된 바 있다. 생김새는 관상의 껍질조각으로 바깥 면은 어두운 갈색 또는 자색을 띤 갈색이며 가로로 길고 작은 타원형의 곁뿌리 자국과 세로주름이 있다. 안쪽 면은 엷은 회갈색이나 어두운 자색을 띠고 편평하며 꺾은 면은 거칠다. 안쪽 면 및 꺾은 면에는 때때로 흰색의 결정이 붙어 있다.Moutan bark is a medicinal material made from the root bark of the peony (Paeonia suffruticosa Andrews) of the peony family, and is used in China and Japan as well as in Korea. Mokdanpi is used for menstrual irregularities due to blood fever, menstrual cramps, bruises, hematemesis, nosebleeds, spots, bone aches due to fever, blood pressure increase, blood elimination, bruises, anti-inflammatory analgesia, abscess treatment, and early appendicitis. It is known to relieve chest discomfort. As for the pharmacological action, analgesic, sedative, antipyretic, anticonvulsant, anti-inflammatory, antithrombotic, anti-allergic, gastric juice secretion inhibition, uterine mucosal congestion, and antibacterial action have been reported. Appearance is a piece of tubular bark, the outer surface is dark brown or purplish brown, and there are horizontally long and small oval side root marks and vertical wrinkles. The inner surface is light grayish brown or dark purple, flat, and the bent surface is rough. White crystals are sometimes attached to the inside and bent sides.
계조축은 단풍나무과의 당단풍(Manshurian fullmoon maple)으로 학명은 Acer pseudo-sieboldianum (Paxton) Komarov이다. 낙엽활엽 소교목, 높이는 8m 가량이고, 잎은길이 7-10㎝, 9-10갈래로 나누워져 있고, 어린잎의 뒷면과 가지에 털이 밀생하고 있으며, 꽃은 암수한그루, 5월 자홍색, 꽃받침은 5-6개로 털이 존재하고 꽃잎은 4장으로 이루어져 있다. 한약재료 수피 부분을 사용하고 본 발명의 계조축 추출물도 수피 부분을 사용한 것이다.The gradation axis is Manshurian fullmoon maple of the Maple family, and its scientific name is Acer pseudo-sieboldianum (Paxton) Komarov. Deciduous broad-leaved small tree, height of about 8m, leaves are 7-10cm long, divided into 9-10 branches, hairs grow densely on the backside of young leaves and branches, flowers are hermaphrodite, magenta in May, calyx is There are 5-6 hairs, and the petals are composed of 4 sheets. The bark part of the herbal medicinal material is used, and the bark part is also used for the extract of the goldenrod of the present invention.
연교는 물푸레나무과의 의성개나리(Forsythia viridissima Lindley) 또는 당개나리(Forsythia suspensa Vahl)의 건조시킨 열매를 의미한다. 연교는 열매가 연꽃과 비슷하게 방을 형성하고 있고 여러 풀 중에 길게 솟아나와 있어 얻은 이름이다. 특이한 냄새가 있으며 그 맛은 쓰고, 기운은 약간 차다. 약효는 열을 내리고 해독하며, 풍열을 없애고, 종기나 상처가 부은 것을 삭도록 하거나 뭉치거나 몰린것을 풀어주는 소종산결 효능을 갖는다고 알려져 있다. 약리작용으로 항균작용, 항염증작용, 혈압강하, 지혈작용, 간치료작용, 해열, 진토, 이뇨작용이 보고되었다. 주요 화학성분으로는 포르시톨(forsythol), 스테롤(sterol) 화합물, 사포닌(saponin), 올레아놀산(oleanolic acid) 등이 있다.Yeongyo refers to the dried fruit of Forsythia viridissima Lindley or Forsythia suspensa Vahl of the ash family. Yeongyo got its name because the fruit forms a room similar to a lotus flower and protrudes long among various grasses. It has a peculiar smell, the taste is bitter, and the energy is slightly cold. It is known that it has the effect of lowering heat and detoxifying, eliminating wind fever, removing boils or wounds, or releasing clumps or lumps. As for the pharmacological action, antibacterial action, anti-inflammatory action, blood pressure lowering, hemostatic action, liver treatment action, antipyretic action, antiemetic action, and diuretic action have been reported. Major chemical components include forsythol, sterol compounds, saponin, and oleanolic acid.
상기 도고온천수를 포함하는 배지는 상기 도고온천수를 10 내지 40 %(v/v) 포함하는 것이 바람직하고, 더욱 바람직하게는 25 내지 35 %(v/v) 포함시킬 수 있다. 10 %(v/v) 미만인 경우에는 주름 개선 또는 미백 효과가 저하될 수 있고, 40 %(v/v)을 초과하는 경우에는 프로바이오틱스의 배양이 어려울 수 있다.The medium containing the Dogo hot spring water preferably contains 10 to 40% (v/v) of the Dogo hot spring water, more preferably 25 to 35% (v/v). If it is less than 10% (v/v), wrinkle improvement or whitening effect may be reduced, and if it exceeds 40% (v/v), it may be difficult to culture probiotics.
또한, 상기 도고온천수를 포함하는 배지는 상기 한약재 추출물을 1 내지 5 %(v/v) 포함하고, 상기 한약재 추출물은 고형분 함량이 10 내지 20%(w/v)인 것이 바람직하고, 더욱 바람직하게는 상기 한약재 추출물을 2 내지 4 %(v/v) 포함하고, 상기 한약재 추출물은 고형분 함량이 12 내지 17%(w/v) 일 수 있다. 상기 한약재 추출물이 1 %(v/v) 미만으로 포함되는 경우 주름 개선 또는 미백 효과가 저하될 수 있고, 5 %(v/v) 초과하는 경우에는 피부 독성이 생기거나 프로바이오틱스의 배양이 제대로 이루어지지 않을 수 있다.In addition, the medium containing the Dogo hot spring water contains 1 to 5% (v / v) of the herbal medicine extract, the herbal medicine extract preferably has a solid content of 10 to 20% (w / v), more preferably Contains 2 to 4% (v / v) of the herbal medicine extract, and the herbal medicine extract may have a solid content of 12 to 17% (w / v). If the herbal medicine extract is included in less than 1% (v / v), wrinkle improvement or whitening effect may be reduced, and if it exceeds 5% (v / v), skin toxicity may occur or probiotics may not be cultured properly. may not be
상기 락토바실러스(Lactobacillus) 속 균주는 락토바실러스 플란타룸(Lactobacillus plantarum), 락토바실러스 루테리(Lactobacillus reuteri), 락토바실러스 하비넨시스(Lactobacillus harbinensis), 락토바실러스 카세이(Lactobacillus casei), 락토바실러스 사케이(Lactobacillus sakei), 락토바실러스 브레비스(Lactobacillus brevis), 락토바실러스 펜토서스(Lactobacillus pentosus), 락토바실러스 퍼멘텀(Lactobacillus fermentum), 락토바실러스 애시도필러스(Lactobacillus acidophilus) 및 락토바실러스 람노서스(Lactobacillus rhamnosus) 중에서 선택된 어느 하나인 것이 바람직하고, 더욱 바람직하게는 락토바실러스 플란타룸(Lactobacillus plantarum) 일 수 있다.The strains of the genus Lactobacillus include Lactobacillus plantarum , Lactobacillus reuteri , Lactobacillus harbinensis , Lactobacillus casei , Lactobacillus sake ( Among Lactobacillus sakei ), Lactobacillus brevis , Lactobacillus pentosus , Lactobacillus fermentum , Lactobacillus acidophilus and Lactobacillus rhamnosus It is preferably any selected one, more preferably Lactobacillus plantarum ( Lactobacillus plantarum ).
상기 락토바실러스 플란타룸(Lactobacillus plantarum)은 인체에 유용한 대사산물을 만들어내고 식품 원료로도 사용될 정도로 안전한 균이다. 본 발명의 락토바실러스 플란타룸 배양 추출물은 상기 락토바실러스 플란타룸을 배양하여 호모게나이저로 세포를 파쇄하여 얻은 것으로서, 락토바실러스 플란타룸의 대사성분, 세포질, 세포벽성분, 다당체 등이 함유되어 있는 발효 용해물이다.The Lactobacillus plantarum is a bacterium that is safe enough to produce useful metabolites for the human body and to be used as a food raw material. The Lactobacillus plantarum culture extract of the present invention is obtained by culturing the Lactobacillus plantarum and disrupting the cells with a homogenizer, and contains metabolic components, cytoplasm, cell wall components, polysaccharides, etc. of Lactobacillus plantarum It is a fermentation lysate in
또한, 상기 비피도박테리움(Bifidobacterium) 속 균주는 비피도박테리움 롱검(Bifidobacterium longum), 비피도박테리움 브레베(Bifidobacterium breve), 비피도박테리움 락티스(Bifidobacterium lactis), 및 비피도박테리움 비피덤(Bifidobacterium bifidum) 중에서 선택된 어느 하나인 것이 바람직하고, 더욱 바람직하게는 비피도박테리움 롱검(Bifidobacterium longum) 일 수 있다.In addition, the strains of the Bifidobacterium genus include Bifidobacterium longum, Bifidobacterium breve , Bifidobacterium lactis , and Bifidobacterium It is preferably any one selected from Bifidobacterium bifidum , and more preferably Bifidobacterium longum .
비피도박테리움 롱검(Bifidobacterium longum)은 인간의 위장관에 존재하는 그람 양성 유산균으로 인체에서 분리되어 안정성이 입증되었으며, 장 환경을 개선하는 유익균으로도 알려져 있다.Bifidobacterium longum ( Bifidobacterium longum ) is a gram-positive lactic acid bacterium that exists in the human gastrointestinal tract and has been isolated from the human body and has proven its stability, and is also known as a beneficial bacterium that improves the intestinal environment.
상기 도고온천수는 칼슘(Ca) 55 내지 65 mg/L, 나트륨(Na) 25 내지 35 mg/L, 실리콘(Si) 10 내지 20 mg/L, 리튬(Li) 0.001 내지 0.05 mg/L 및 스트론튬(Sr) 1.0 내지 2.0 mg/L를 포함하는 것을 특징으로 한다.The Dogo hot spring water contains 55 to 65 mg/L of calcium (Ca), 25 to 35 mg/L of sodium (Na), 10 to 20 mg/L of silicon (Si), 0.001 to 0.05 mg/L of lithium (Li) and strontium ( Sr) characterized in that it comprises 1.0 to 2.0 mg / L.
본 발명의 화장료 조성물은 피부 미백 또는 주름 개선용인 것을 특징으로 한다.The cosmetic composition of the present invention is characterized in that it is for skin whitening or wrinkle improvement.
본 명세서에서 사용되는 용어 “추출물”은 추출용매를 처리하여 얻은 조추출물뿐만 아니라 추출물의 가공물도 포함한다. 예를 들어, 추출물은 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조될 수 있다.The term "extract" used herein includes not only a crude extract obtained by treating an extraction solvent, but also a processed product of the extract. For example, the extract can be prepared in a powder state by additional processes such as vacuum distillation and freeze drying or spray drying.
또한, 본 발명의 목단피, 계조축, 연교를 포함하는 한약재 추출물은 광의로는 제형화된 가공물, 예컨대, 한약재 분말도 포함하는 의미를 갖는다. 비록 본 발명에서 한약재로 실험을 진행하긴 하였으나, 한약재 가공물과 같은 형태로도 목적하는 효과를 달성할 수 있음은 당업자라면 예상 가능할 것이다.In addition, the herbal medicine extract including Mokdanpi, Gyejochuk, and Yeongyo of the present invention has the meaning of including formulated processed products, such as herbal medicine powder, in a broad sense. Although the experiment was conducted with herbal medicines in the present invention, it would be expected by those skilled in the art that the desired effect could be achieved even in the same form as the herbal medicine processed product.
한편, 본 명세서에서 용어 “유효성분으로 포함하는”이란 프로바이오틱스 배양물을 포함하는 성분의 효능 또는 활성을 달성하는 데 충분한 양을 포함하는 것을 의미한다. 일예로, 상기 프로바이오틱스 배양물을 포함하는 10 내지 1500 ㎍/㎖, 바람직하게는 100 내지 1000 ㎍/㎖의 농도로 사용된다. 프로바이오틱스 배양물은 천연물로서 과량 피부에 적용하여도 인체에 부작용이 없으므로 본 발명의 조성물 내에 포함되는 프로바이오틱스 배양물의 양적 상한은 당업자가 적절한 범위 내에서 선택하여 실시할 수 있다.On the other hand, in the present specification, the term "comprising as an active ingredient" means including a sufficient amount to achieve the efficacy or activity of the ingredient containing the probiotics culture. For example, it is used at a concentration of 10 to 1500 μg/ml, preferably 100 to 1000 μg/ml, including the probiotics culture. Since the probiotics culture is a natural product and does not have side effects on the human body even when applied to the skin in excess, the quantitative upper limit of the probiotics culture included in the composition of the present invention can be selected and implemented by those skilled in the art within an appropriate range.
본 발명에서 사용된 용어인 "피부 미백"이란, 피부를 희게 하는 것으로서, 사람의 피부색은 피부 내부의 멜라닌(melanin) 농도와 분포에 따라 결정되는데, 유전적인 요인 외에도, 태양 자외선이나 피로, 스트레스 등의 환경적 또는 생리적 조건에 의해서도 영향을 받는다. 멜라닌은 피부 표피층에 있는 멜라노사이트에서 합성되는데, 멜라노사이트 내 소기관인 멜라노좀(melanosome)에서 아미노산의 일종인 티로신(tyrosine)에 티로시나제(tyrosinase)라는 효소가 작용하여 도파(DOPA), 도파퀴논(dopaquinone)으로 바뀐 후 비효소적인 산화반응을 거쳐 만들어진다. 이와 같은 멜라닌의 합성이 피부 내에서 과도하게 일어나면, 피부 톤을 어둡게 하고, 기미, 주근깨 등을 발생시킨다. 따라서, 피부 내의 티로시나제 활성을 저해하여 멜라닌 색소의 합성을 저해시키면, 피부 톤을 밝게 하여 피부 미백을 실현할 수 있을 뿐만 아니라 자외선, 호르몬 및 유전적인 원인에 기인하여 발생하는 기미, 주근깨 등의 피부 과색소 침착증을 개선시킬 수 있다.The term "skin whitening" used in the present invention is to whiten the skin, and the skin color of a person is determined by the concentration and distribution of melanin inside the skin. In addition to genetic factors, solar ultraviolet radiation, fatigue, stress, etc. are also affected by environmental or physiological conditions. Melanin is synthesized in melanocytes in the epidermal layer of the skin. An enzyme called tyrosinase acts on tyrosine, a kind of amino acid, in melanosomes, organelles in melanocytes, to produce DOPA and dopaquinone. ) and then produced through a non-enzymatic oxidation reaction. When such melanin synthesis occurs excessively in the skin, the skin tone is darkened, and spots, freckles, and the like are generated. Therefore, if the synthesis of melanin pigment is inhibited by inhibiting the activity of tyrosinase in the skin, skin whitening can be realized by brightening the skin tone, as well as skin hyperpigmentation such as spots and freckles caused by ultraviolet rays, hormones, and genetic causes. It can improve depression.
또한, 본 발명에서 용어, "주름"이란, 피부가 쇠하여 생긴 잔줄을 의미하는데, 유전자에 의한 원인, 피부 진피에 존재하는 콜라겐의 감소, 외부 환경 등에 의해 유발될 수 있다. 본 발명에서 "주름 개선"이란, 피부에 주름이 생성되는 것을 억제 또는 저해하거나, 이미 생성된 주름을 완화시키는 것을 말한다.In addition, the term "wrinkle" in the present invention refers to fine lines caused by skin deterioration, which may be caused by genes, reduction of collagen present in the skin dermis, external environment, and the like. In the present invention, "wrinkle improvement" refers to inhibiting or inhibiting the formation of wrinkles on the skin, or alleviating wrinkles already formed.
피부 섬유아세포의 주된 기능으로 세포외기질 합성과 증식을 통한 손상된 피부 조직 재생 등을 들 수 있는데, 광노화와 같은 외인성 노화 요인 또는 유리 산소에 의한 손상 누적, 텔로미어 단절로 인한 세포 노화 등에 따른 내인성 노화 요인들은 진피층 내에 있는 피부섬유아세포의 생리 활성 기능을 저하시키게 된다. 피부 세포외기질 중 95% 이상을 차지하고, 세포의 부착분자(adhesion molecule) 및 세포 골격(cytoskeleton) 등과의 상호 작용과 신호 교류를 통해 섬유아세포의 생리 활성에 매우 주요한 부분을 담당하는 제I형 콜라겐의 합성이 저하될 경우, 피부 조직 내 콜라겐 양이 감소되고, 이에 따라 표면 장력이 감소되어 피부 탄력이 저하되고 피부 주름이 형성될 뿐만 아니라, 세포의 증식 및 재생 기능을 포함하는 생리 활성 기능이 감소하는 악순환의 원인이 된다.The main function of skin fibroblasts is to regenerate damaged skin tissue through extracellular matrix synthesis and proliferation. Extrinsic aging factors such as photoaging or endogenous aging factors such as accumulation of free oxygen damage and cell aging due to telomere disruption They lower the physiological activity of dermal fibroblasts in the dermal layer. Type I collagen, which accounts for more than 95% of skin extracellular matrix and plays a very important part in the physiological activity of fibroblasts through interaction and signal exchange with adhesion molecules and cytoskeleton of cells When the synthesis of collagen is reduced, the amount of collagen in the skin tissue is reduced, and as a result, the surface tension is reduced, resulting in a decrease in skin elasticity and formation of skin wrinkles, as well as a decrease in physiologically active functions including cell proliferation and regeneration. cause a vicious cycle of
따라서, 피부섬유아세포의 콜라겐은 피부 재생, 피부 탄력, 피부 주름 형성 및 피부 손상 시 조직의 수복 또는 재생과 직접적인 관련이 있다고 볼 수 있다. 즉, 피부 섬유아세포의 콜라겐 또는 프로콜라겐의 합성이 촉진되거나, 콜라겐을 분해하는 기질 단백질 분해효소(matrix metallo-proteinase, 이하 'MMP'라 함)의 합성이 저해되면, 피부 탄력 개선, 피부 재생, 피부 주름 개선, 상처 치유, 손상된 피부 조직의 수복 및 재생; 및 피부 노화 방지 등의 효과를 얻을 수 있다.Therefore, collagen of dermal fibroblasts can be directly related to skin regeneration, skin elasticity, skin wrinkle formation, and tissue repair or regeneration upon skin damage. That is, when the synthesis of collagen or procollagen in skin fibroblasts is promoted or the synthesis of matrix metallo-proteinase (hereinafter referred to as 'MMP') that degrades collagen is inhibited, skin elasticity is improved, skin regeneration, skin wrinkle improvement, wound healing, repair and regeneration of damaged skin tissue; And effects such as skin aging prevention can be obtained.
본 발명의 화장료 조성물은 타입 I 프로콜라겐 단백질의 발현을 증가시키고, MMP-1 단백질의 발현을 억제하는 것을 특징으로 한다. 구체적으로, 본 발명의 상기 화장료 조성물은 콜라겐 분해를 촉진시키는 기질 단백질 분해효소-1(matrix metallo-proteinase)의 발현을 억제시키면서, 타입 Ⅰ 프로콜라겐의 생성을 증가시키는바, 피부 탄력 증가, 피부 재생, 피부 주름 개선, 상처 치유, 손상된 피부 조직의 수복 및 재생; 및 피부 노화 방지 등의 효과 등을 가질 수 있다. 즉, 피부주름의 예방 또는 개선의 효과를 가질 수 있다.The cosmetic composition of the present invention is characterized by increasing the expression of type I procollagen protein and suppressing the expression of MMP-1 protein. Specifically, the cosmetic composition of the present invention suppresses the expression of matrix metallo-proteinase, which promotes collagen degradation, while increasing the production of type I procollagen, thereby increasing skin elasticity and regenerating skin. , skin wrinkle improvement, wound healing, repair and regeneration of damaged skin tissue; And it may have effects such as skin aging prevention. That is, it may have an effect of preventing or improving skin wrinkles.
이외에도 본 발명의 화장료 조성물은 수용성 비타민, 지용성 비타민, 고분자 펩티드, 고분자 다당, 스핑고 지질 및 해초 엑기스 등을 더 포함할 수 있다.In addition, the cosmetic composition of the present invention may further include water-soluble vitamins, fat-soluble vitamins, high-molecular peptides, high-molecular polysaccharides, sphingolipids, and seaweed extracts.
상기 수용성 비타민으로는 화장품에 배합 가능한 것이라면 어떠한 것도 될 수 있으나, 바람직하게는 비타민 B1, 비타민 B2, 비타민 B6, 피리독신, 염산피리독신, 비타민 B12, 판토텐산, 니코틴산, 니코틴산아미드, 엽산, 비타민 C, 비타민 H 등을 들 수 있으며, 그들의 염(티아민염산염, 아스코르빈산나트륨염 등)이나 유도체(아스코르빈산-2-인산나트륨염, 아스코르빈산-2-인산마그네슘염 등)도 본 발명에서 사용할 수 있는 수용성 비타민에 포함된다. 상기 수용성 비타민은 미생물 변환법, 미생물 배양물의 정제법, 효소법 또는 화학 합성법 등의 통상의 방법에 의해 수득할 수 있다.Any water-soluble vitamin may be used as long as it can be formulated into cosmetics, but preferably vitamin B1, vitamin B2, vitamin B6, pyridoxine, pyridoxine hydrochloride, vitamin B12, pantothenic acid, nicotinic acid, nicotinic acid amide, folic acid, vitamin C, vitamin H and the like, and their salts (thiamin hydrochloride, ascorbic acid sodium salt, etc.) or derivatives (ascorbic acid-2-phosphate sodium salt, ascorbic acid-2-phosphate magnesium salt, etc.) can also be used in the present invention. Included in water-soluble vitamins. The water-soluble vitamin can be obtained by conventional methods such as microbial transformation, microbial culture purification, enzymatic or chemical synthesis.
상기 지용성 비타민으로는 화장품에 배합 가능한 것이라면 어떠한 것도 될 수 있으나, 바람직하게는 비타민 A, 카로틴, 비타민 D2, 비타민 D3, 비타민 E 등을 들 수 있으며, 그들의 유도체(팔미틴산아스코르빈, 스테아르산아스코르빈, 디팔미틴산아스코르빈, 아세트산dl-알파 토코페롤, 니코틴산dl-알파 토코페롤비타민 E, DL-판토테닐알코올, D-판토테닐알코올, 판토테닐에틸에테르 등) 등도 본 발명에서 사용되는 지용성 비타민에 포함된다.The fat-soluble vitamin may be any substance as long as it can be formulated into cosmetics, but preferably includes vitamin A, carotene, vitamin D2, vitamin D3, vitamin E, etc., and their derivatives (ascorbic acid palmitate, ascorbic acid stearate). Bean, ascorbine dipalmitate, dl-alpha tocopherol acetate, dl-alpha tocopherol nicotinate, vitamin E, DL-pantothenyl alcohol, D-pantothenyl alcohol, pantothenyl ethyl ether, etc.) are also included in the fat-soluble vitamins used in the present invention. do.
상기 고분자 펩티드로는 화장품에 배합 가능한 것이라면 어떠한 것도 될 수 있으나, 바람직하게는 콜라겐, 가수분해 콜라겐, 젤라틴, 엘라스틴, 가수 분해 엘라스틴, 케라틴 등을 들 수 있다. 상기 고분자 펩티드는 미생물 배양액의 정제법, 효소법 또는 화학 합성법 등의 통상의 방법에 의해 정제 취득할 수 있으며, 또는 통상 돼지나 소 등의 진피, 누에의 견 섬유 등의 천연물로부터 정제하여 사용할 수 있다.The polymer peptide may be anything as long as it can be incorporated into cosmetics, but preferably includes collagen, hydrolyzed collagen, gelatin, elastin, hydrolyzed elastin, keratin, and the like. The polymeric peptide can be purified and obtained by a conventional method such as a microbial culture solution purification method, an enzyme method, or a chemical synthesis method, or can be used after being purified from a natural product such as pig or cow dermis or silkworm silk fiber.
상기 고분자 다당에는 화장품에 배합 가능한 것이라면 어떠한 것도 될 수 있으나, 바람직하게는 히드록시에틸셀룰로오스, 크산탄검, 콘드로이틴 황산 또는 그 염(나트륨염 등) 등을 들 수 있다. 예를 들어, 콘드로이틴 황산 또는 그 염 등은 통상 포유동물이나 어류로부터 정제하여 사용할 수 있다.The polymeric polysaccharide may be anything as long as it can be formulated into cosmetics, but preferably includes hydroxyethyl cellulose, xanthan gum, chondroitin sulfate or a salt thereof (sodium salt, etc.). For example, chondroitin sulfate or a salt thereof can be used after being purified from mammals or fish.
상기 스핑고 지질로는 화장품에 배합 가능한 것이라면 어떠한 것도 될 수 있으나, 바람직하게는 세라미드, 피토스핑고신, 스핑고당 지질 등을 들 수 있다. 상기 스핑고 지질은 통상 포유류, 어류, 패류, 효모 또는 식물 등으로부터 통상의 방법에 의해 정제하거나 화학 합성법에 의해 취득할 수 있다.The sphingolipid may be any material as long as it can be formulated into cosmetics, but preferably includes ceramide, phytosphingosine, sphingosaccharide lipid, and the like. The sphingolipids can be purified by conventional methods or obtained by chemical synthesis from mammals, fish, shellfish, yeast or plants.
상기 해초 엑기스로는 화장품에 배합 가능한 것이라면 어떠한 것도 될 수 있으나, 바람직하게는 갈조 엑기스, 홍조엑기스, 녹조 엑기스 등을 들 수 있으며, 또한, 이들의 해초 엑기스로부터 정제된 칼라기난, 아르긴산, 아르긴산나트륨, 아르긴산칼륨 등도 본 발명에서 사용되는 해초 엑기스에 포함된다. 해초 엑기스는 해초로부터 통상의 방법에 의해 정제하여 취득할 수 있다.The seaweed extract may be anything as long as it can be formulated into cosmetics, but preferably brown algae extract, red algae extract, green algae extract, etc., and also calrageenan, arginic acid, and arginic acid purified from these seaweed extracts Sodium, potassium alginate, etc. are also included in the seaweed extract used in the present invention. Seaweed extract can be obtained by purifying from seaweed by a conventional method.
본 발명의 화장료 조성물에는 상기 필수 성분과 더불어 필요에 따라 통상 화장료에 배합되는 다른 성분을 배합할 수 있다.In the cosmetic composition of the present invention, in addition to the above essential components, other ingredients commonly used in cosmetics may be mixed as necessary.
이외에 첨가해도 되는 배합 성분으로서는 유지 성분, 보습제, 에몰리엔트제, 자외선 흡수제, pH 조정제, 향료, 혈행 촉진제, 냉감제, 제한제, 정제수 등을 들 수 있다.Other ingredients that may be added include fats and oils, humectants, emollients, ultraviolet absorbers, pH adjusters, fragrances, blood circulation promoters, cooling agents, antiperspirants, and purified water.
상기 유지 성분으로는 에스테르계 유지, 탄화수소계 유지, 실리콘계 유지, 불소계 유지, 동물 유지, 식물 유지 등을 들 수 있다.Examples of the oil and fat component include ester oil, hydrocarbon oil, silicone oil, fluorine oil, animal fat and vegetable oil.
상기 에스테르계 유지로는 트리2-에틸헥산산글리세릴, 2-에틸헥산산세틸, 미리스틴산이소프로필, 미리스틴산부틸, 팔미틴산이소프로필, 스테아르산에틸, 팔미틴산옥틸, 이소스테아르산이소세틸, 스테아르산부틸, 리놀레산에틸, 리놀레산이소프로필, 올레인산에틸, 미리스틴산이소세틸, 미리스틴산이소스테아릴, 팔미틴산이소스테아릴, 미리스틴산옥틸도데실, 이소스테아르산이소세틸, 세바신산디에틸, 아디핀산디이소프로필, 네오펜탄산이소알킬, 트리(카프릴, 카프린산)글리세릴, 트리2-에틸헥산산트리메틸롤프로판, 트리이소스테아르산트리메틸롤프로판, 테트라2-에틸헥산산펜타엘리슬리톨, 카프릴산세틸, 라우린산데실, 라우린산헥실, 미리스틴산데실, 미리스틴산미리스틸, 미리스틴산세틸, 스테아르산스테아릴, 올레인산데실, 리시노올레인산세틸, 라우린산이소스테아릴, 미리스틴산이소트리데실, 팔미틴산이소세틸, 스테아르산옥틸, 스테아르산이소세틸, 올레인산이소데실, 올레인산옥틸도데실, 리놀레산옥틸도데실, 이소스테아르산이소프로필, 2-에틸헥산산세토스테아릴, 2-에틸헥산산스테아릴, 이소스테아르산헥실, 디옥탄산에틸렌글리콜, 디올레인산에틸렌글리콜, 디카프린산프로필렌글리콜, 디카프릴산프로필렌글리콜, 디카프린산네오펜틸글리콜, 디옥탄산네오펜틸글리콜, 트리카프릴산글리세릴, 트리운데실산글리세릴, 트리이소팔미틴산글리세릴, 트리이소스테아르산글리세릴, 네오펜탄산옥틸도데실, 옥탄산이소스테아릴, 이소노난산옥틸, 네오데칸산헥실데실, 네오데칸산옥틸도데실, 이소스테아르산이소세틸, 이소스테아르산이소스테아릴, 이소스테아르산옥틸데실, 폴리글리세린올레인산에스테르, 폴리글리세린이소스테아르산에스테르, 시트르산트리이소세틸, 시트르산트리이소알킬, 시트르산트리이소옥틸, 락트산라우릴, 락트산미리스틸, 락트산세틸, 락트산옥틸데실, 시트르산트리에틸, 시트르산아세틸트리에틸, 시트르산아세틸트리부틸, 시트르산트리옥틸, 말산디이소스테아릴, 히드록시스테아르산 2-에틸헥실, 숙신산디2-에틸헥실, 아디핀산디이소부틸, 세바신산디이소프로필, 세바신산디옥틸, 스테아르산콜레스테릴, 이소스테아르산콜레스테릴, 히드록시스테아르산콜레스테릴, 올레인산콜레스테릴, 올레인산디히드로콜레스테릴, 이소스테아르산피트스테릴, 올레인산피트스테릴, 12-스테알로일히드록시스테아르산이소세틸, 12-스테알로일히드록시스테아르산스테아릴, 12-스테알로일히드록시스테아르산이소스테아릴 등의 에스테르계 등을 들 수 있다.Examples of the ester-based oils include tri-2-ethylhexanoate glyceryl, 2-ethylhexanoate, isopropyl myristate, butyl myristate, isopropyl palmitate, ethyl stearate, octyl palmitate, isostearate isocetyl, Butyl stearate, ethyl linoleate, isopropyl linoleate, ethyl oleate, isocetyl myristate, isostearyl myristate, isostearyl palmitate, octyldodecyl myristate, isocetyl isostearate, diethyl sebacate, Diisopropyl adipate, isoalkyl neopentanoate, tri(capryl, capric acid) glyceryl, trimethylolpropane tri2-ethylhexanoate, trimethylolpropane triisostearate, tetraethyl 2-ethylhexanoate pentaelli Slitol, cetyl caprylate, decyl laurate, hexyl laurate, decyl myristate, myristyl myristate, cetyl myristate, stearyl stearate, decyl oleate, cetyl ricinooleate, lauric acid sostearyl, isotridecyl myristate, isocetyl palmitate, octyl stearate, isocetyl stearate, isodecyl oleate, octyldodecyl oleate, octyldodecyl linoleate, isopropyl isostearate, 2-ethylhexanoate Tostearyl, 2-ethylstearyl hexanoate, hexyl isostearate, ethylene glycol dioctanoate, ethylene glycol dioleate, propylene glycol dicaprate, propylene glycol dicaprylate, neopentyl glycol dicaprate, neopentyl dioctanoate Glycol, glyceryl tricaprylate, glyceryl triundecylate, glyceryl triisopalmitate, glyceryl triisostearate, octyldodecyl neopentanoate, isostearyl octanoate, octyl isononanoate, hexyl neodecanoate Decyl, octyldodecyl neodecanoate, isocetyl isostearate, isostearyl isostearate, octyldecyl isostearate, polyglycerin oleate, polyglycerin isostearate, triisocetyl citrate, triisoalkyl citrate, Triisooctyl citrate, lauryl lactate, myristyl lactate, cetyl lactate, octyldecyl lactate, triethyl citrate, acetyl triethyl citrate, acetyl tributyl citrate, trioctyl citrate, diisostearyl malate, hydroxystearate 2- Ethylhexyl, di2-ethylhexyl succinate, diisobutyl adipate, diisopropyl sebacate, dioctyl sebacate, cholesteryl stearate, isostear Cholesteryl acid, cholesteryl hydroxystearate, cholesteryl oleate, dihydrocholesteryl oleate, phyteryl isostearate, physteryl oleate, isocetyl 12-stealoylhydroxystearate, 12 - Ester systems, such as stearyl stealoyl hydroxy stearate and isostearyl 12-stealoyl hydroxy stearate, etc. are mentioned.
상기 탄화 수소계 유지로는 스쿠알렌, 유동 파라핀, 알파-올레핀올리고머, 이소파라핀, 세레신, 파라핀, 유동 이소파라핀, 폴리부덴, 마이크로 크리스탈린 왁스, 와셀린 등의 탄화 수소계 유지 등을 들 수 있다.Examples of the hydrocarbon-based fats and oils include hydrocarbon-based fats and oils such as squalene, liquid paraffin, alpha-olefin oligomer, isoparaffin, ceresin, paraffin, liquid isoparaffin, polybuden, microcrystalline wax, and vaseline.
상기 실리콘계 유지로는 폴리메틸실리콘, 메틸페닐실리콘, 메틸시클로폴리실록산, 옥타메틸폴리실록산, 데카메틸폴리실록산, 도데카메틸시클로실록산, 디메틸실록산 메틸세틸옥시실록산 공중합체, 디메틸실록산 메틸스테알록시실록산 공중합체, 알킬 변성 실리콘유, 아미노 변성 실리콘유 등을 들 수 있다.Examples of the silicone-based oil include polymethylsilicone, methylphenylsilicone, methylcyclopolysiloxane, octamethylpolysiloxane, decamethylpolysiloxane, dodecamethylcyclosiloxane, dimethylsiloxane methylcetyloxysiloxane copolymer, dimethylsiloxane methylstealoxysiloxane copolymer, alkyl Modified silicone oil, amino modified silicone oil, etc. are mentioned.
상기 불소계 유지로는 퍼플루오로폴리에테르 등을 들 수 있다.Examples of the fluorine-based fats and oils include perfluoropolyether and the like.
상기 동물 또는 식물 유지로는 아보카도유, 아르몬드유, 올리브유, 참깨유, 쌀겨유, 대두유, 옥수수유, 유채유, 행인유, 팜핵유, 팜유, 피마자유, 해바라기유, 포도종자유, 면실유, 야자유, 쿠쿠이너트유, 소맥배아유, 쌀 배아유, 시아버터, 월견초유, 마커데이미아너트유, 난황유, 우지, 마유, 밍크유, 오렌지라피유, 호호바유, 캔데리러왁스, 카르나바왁스, 액상 라놀, 경화피마자유 등의 동물 또는 식물 유지를 들 수 있다.The animal or vegetable oils include avocado oil, almond oil, olive oil, sesame oil, rice bran oil, soybean oil, corn oil, rapeseed oil, apricot oil, palm kernel oil, palm oil, castor oil, sunflower oil, grape seed oil, cottonseed oil, palm oil, Kukui nut oil, wheat germ oil, rice germ oil, shea butter, moonshine colostrum, marker daemia nut oil, egg yolk oil, beef tallow, horse oil, mink oil, orange raffia oil, jojoba oil, candelilla wax, carnaba wax, liquid lanol , animal or vegetable fats and oils such as hydrogenated castor oil.
상기 보습제로는 수용성 저분자 보습제, 지용성 분자 보습제, 수용성 고분자, 지용성 고분자 등을 들 수 있다.Examples of the moisturizer include water-soluble low-molecular moisturizers, fat-soluble molecular moisturizers, water-soluble polymers, and oil-soluble polymers.
상기 수용성 저분자 보습제로는 세린, 글루타민, 솔비톨, 만니톨, 피롤리돈-카르복실산나트륨, 글리세린, 프로필렌글리콜, 1,3-부틸렌글리콜, 에틸렌글리콜, 폴리에틸렌글리콜B(중합도 n = 2 이상), 폴리프로필렌글리콜(중합도 n = 2 이상), 폴리글리세린B(중합도 n = 2 이상), 락트산, 락트산염 등을 들 수 있다.The water-soluble low-molecular moisturizers include serine, glutamine, sorbitol, mannitol, pyrrolidone-sodium carboxylate, glycerin, propylene glycol, 1,3-butylene glycol, ethylene glycol, polyethylene glycol B (polymerization degree n = 2 or more), Polypropylene glycol (polymerization degree n = 2 or more), polyglycerol B (polymerization degree n = 2 or more), lactic acid, lactate, etc. are mentioned.
상기 지용성 저분자 보습제로는 콜레스테롤, 콜레스테롤에스테르 등을 들 수 있다.Examples of the fat-soluble low-molecular moisturizers include cholesterol and cholesterol esters.
상기 수용성 고분자로는 카르복시비닐폴리머, 폴리아스파라긴산염, 트라가칸트, 크산탄검, 메틸셀룰로오스, 히드록시메틸셀룰로오스, 히드록시에틸셀룰로오스, 히드록시프로필셀룰로오스, 카르복시메틸셀룰로오스, 수용성키틴, 키토산, 덱스트린 등을 들 수 있다.Examples of the water-soluble polymer include carboxyvinyl polymer, polyaspartate, tragacanth, xanthan gum, methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, water-soluble chitin, chitosan, dextrin, etc. can be heard
상기 지용성 고분자로는 폴리비닐피롤리돈 에이코센 공중합체, 폴리비닐피롤리돈 헥사데센 공중합체, 니트로셀룰로오스, 덱스트린지방산에스테르, 고분자 실리콘 등을 들 수 있다.Examples of the fat-soluble polymer include polyvinylpyrrolidone eicosene copolymer, polyvinylpyrrolidone hexadecene copolymer, nitrocellulose, dextrin fatty acid ester, polymeric silicone, and the like.
상기 에몰리엔트제로는 장쇄아실글루타민산콜레스테릴에스테르, 히드록시스테아르산콜레스테릴, 12-히드록시스테아르산, 스테아르산, 로진산, 라놀린지방산콜레스테릴에스테르 등을 들 수 있다.Examples of the emollient agent include long-chain acyl glutamic acid cholesteryl ester, hydroxystearic acid cholesteryl, 12-hydroxystearic acid, stearic acid, rosin acid, and lanolin fatty acid cholesteryl ester.
상기 자외선 흡수제로는 파라아미노벤조산, 파라아미노벤조산에틸, 파라아미노벤조산아밀, 파라아미노벤조산옥틸, 살리실산에틸렌글리콜, 살리신산페닐, 살리신산옥틸, 살리신산벤질, 살리신산부틸페닐, 살리신산호모멘틸, 계피산벤질, 파라메톡시계피산-2-에톡시에틸, 파라메톡시계피산옥틸, 디파라메톡시계피산모노-2-에틸헥산글리세릴, 파라메톡시계피산이소프로필, 디이소프로필ㆍ디이소프로필계피산에스테르 혼합물, 우로카닌산, 우로카닌산에틸, 히드록시메톡시벤조페논, 히드록시메톡시벤조페논술폰산 및 그 염, 디히드록시메톡시벤조페논, 디히드록시메톡시벤조페논디술폰산나트륨, 디히드록시벤조페논, 테트라히드록시벤조페논, 4-tert-부틸-4'-메톡시디벤조일메탄, 2,4,6-트리아닐리노-p-(카르보-2'-에틸헥실-1'-옥시)-1,3,5-트리아진, 2-(2-히드록시-5-메틸페닐)벤조트리아졸 등을 들 수 있다.The ultraviolet absorber includes para-aminobenzoic acid, para-aminobenzoic acid ethyl, para-aminobenzoic acid amyl, para-aminobenzoic acid octyl, salicylic ethylene glycol, salicylic acid phenyl, salicylic acid octyl, salicylic acid benzyl, salicylic acid butylphenyl, salicylic acid homomentyl, Benzyl cinnamate, paramethoxycinnamic acid-2-ethoxyethyl, paramethoxycinnamic acid octyl, diparamethoxycinnamic acid mono-2-ethylhexane glyceryl, paramethoxycinnamic acid isopropyl, diisopropyl-diisopropylcinnamic acid ester mixture , urocanic acid, ethyl urocanate, hydroxymethoxybenzophenone, hydroxymethoxybenzophenonesulfonic acid and its salts, dihydroxymethoxybenzophenone, dihydroxymethoxybenzophenone sodium disulfonate, dihydroxy Benzophenone, tetrahydroxybenzophenone, 4-tert-butyl-4'-methoxydibenzoylmethane, 2,4,6-trianilino-p-(carbo-2'-ethylhexyl-1'-oxy) -1,3,5-triazine, 2-(2-hydroxy-5-methylphenyl) benzotriazole, etc. are mentioned.
상기 pH 조정제로는 시트르산, 시트르산나트륨, 말산, 말산나트륨, 프말산, 프말산나트륨, 숙신산, 숙신산나트륨, 수산화나트륨, 인산일수소나트륨 등을 들 수 있다.Examples of the pH adjusting agent include citric acid, sodium citrate, malic acid, sodium malate, fumalic acid, sodium fumalate, succinic acid, sodium succinate, sodium hydroxide, sodium monohydrogenphosphate, and the like.
상기 pH 조정제로는 시트르산, 시트르산나트륨, 말산, 말산나트륨, 프말산, 프말산나트륨, 숙신산, 숙신산나트륨, 수산화나트륨, 인산일수소나트륨 등을 들 수 있다.Examples of the pH adjusting agent include citric acid, sodium citrate, malic acid, sodium malate, fumalic acid, sodium fumalate, succinic acid, sodium succinate, sodium hydroxide, sodium monohydrogenphosphate, and the like.
본 발명의 화장료 조성물을 함유하여 제조된 화장료는 용액, 유화물, 점성형 혼합물 등의 형상을 취할 수 있다.Cosmetics prepared by containing the cosmetic composition of the present invention may take the form of solutions, emulsions, viscous mixtures, and the like.
또한, 본 발명의 상기 화장료 조성물에 포함되는 성분은 유효성분으로서 상기 성분 이외에 화장료 조성물에 통상적으로 이용되는 성분들을 포함할 수 있으며, 예를 들면, 안정화제, 안료 및 천연향료와 같은 통상적인 보조제 및 담체를 더 포함할 수 있다.In addition, the ingredients included in the cosmetic composition of the present invention may include ingredients commonly used in cosmetic compositions in addition to the above ingredients as active ingredients, for example, conventional adjuvants such as stabilizers, pigments and natural flavors, and A carrier may be further included.
본 발명의 화장료 조성물은 피부 미백 또는 주름개선 효과를 갖는 화장품 또는 세안제 등에 다양하게 이용될 수 있다.The cosmetic composition of the present invention can be used in various ways such as cosmetics or facial cleansers having skin whitening or wrinkle improvement effects.
본 발명의 화장료 조성물을 첨가할 수 있는 제품으로는, 예를 들어, BB크림, 스킨로션, 스킨소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스쳐 로션, 영양로션, 맛사지크림, 영양크림, 자외선 차단크림, 모이스처크림, 핸드크림, 파운데이션, 에센스, 영양에센스, 마스크팩 등과 같은 화장품류와 비누, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션 및 바디클린저 등이 있다.Products to which the cosmetic composition of the present invention can be added include, for example, BB cream, skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutrient lotion, massage cream, nutrient cream, and ultraviolet rays. There are cosmetics such as blocking cream, moisture cream, hand cream, foundation, essence, nutrient essence, and mask pack, as well as soap, cleansing foam, cleansing lotion, cleansing cream, body lotion, and body cleanser.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물섬유, 식물섬유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal fiber, vegetable fiber, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as a carrier component. can
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판, 부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, additional chlorofluorohydrocarbon, propane , butane or a propellant such as dimethyl ether.
본 발명의 제형이 용액 또는 유탁액의 경우에는 담체 성분으로서 용매, 용매화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or emulsion, a solvent, solvating agent or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butyl glycol oil, fatty acid esters of glycerol, polyethylene glycol or sorbitan.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, an ethoxylated isostearyl alcohol, a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline Cellulose, aluminum metahydroxide, bentonite, agar or tracanth and the like may be used.
이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시하나, 하기 실시예는 본 발명을 예시하는 것일 뿐 본 발명의 범주 및 기술사상 범위 내에서 다양한 변경 및 수정이 가능함은 당업자에게 있어서 명백한 것이며, 이러한 변형 및 수정이 첨부된 특허청구범위에 속하는 것도 당연한 것이다.Hereinafter, preferred embodiments are presented to aid understanding of the present invention, but the following examples are merely illustrative of the present invention, and various changes and modifications are possible within the scope and spirit of the present invention. It is obvious to those skilled in the art, It goes without saying that these variations and modifications fall within the scope of the appended claims.
[실시예][Example]
제조예 A: 목단피 추출물Preparation Example A: Mudanpi extract
목단피를 잘게 잘라 물과 1:10(w/v)의 비율로 100 ℃에서 4시간 동안 열수추출한 후 부직포로 여과하여 불순물을 제거하고, 고형분 함량이 15% 이상이 되도록 감압 농축하여 목단피 추출물을 제조하였다.Moutan bark was cut into small pieces, followed by hot water extraction at 100 ° C for 4 hours with water at a ratio of 1:10 (w/v), filtering through non-woven fabric to remove impurities, and concentration under reduced pressure to obtain a solid content of 15% or more to prepare the extract of Moutan bark. did
제조예 B: 계조축 추출물Preparation Example B: Gyejo axis extract
목단피 대신에 계조축의 수피를 사용한 것을 제외하고는 제조예 A와 동일한 조건으로 추출하여 계조축 추출물을 제조하였다.An extract was prepared by extracting under the same conditions as in Preparation Example A, except that the bark of the gray axis was used instead of the mudan bark.
제조예 C: 연교 추출물Preparation Example C: Yeongyo Extract
목단피 대신에 연교(Forsythiae Fructus)를 사용한 것을 제외하고는 제조예 A와 동일한 조건으로 추출하여 연교 추출물을 제조하였다.A Forsythiae Fructus extract was prepared by extracting under the same conditions as in Preparation Example A, except that Forsythiae Fructus was used instead of Moutanpi.
제조예 1: 도고온천수를 이용한 락토바실러스 플란타룸 배양물Preparation Example 1: Lactobacillus plantarum culture using Dogo hot spring water
락토바실러스 플란타룸(Lactobacillus plantarum) 균주를 MRS Broth 액체배지 70㎖, 도고온천수 30㎖로 혼합된 혼합배지에 락토바실러스 플란타룸 108 CFU/㎖) 1㎖를 접종하여, 37 ℃에서 30시간 발효시킨 후 배양물을 호모게나이저로 균체를 파쇄하여 락토바실러스 플란타룸 배양물을 수득하였다.Lactobacillus plantarum strain was inoculated with 1 ml of Lactobacillus plantarum 10 8 CFU/ml) in a mixed medium mixed with 70 ml of MRS Broth liquid medium and 30 ml of Dogo hot spring water, and incubated at 37 ° C for 30 hours. After fermentation, the culture was disrupted with a homogenizer to obtain a Lactobacillus plantarum culture.
제조예 2: 도고온천수를 이용한 비피도박테리움 롱검 배양물Preparation Example 2: Bifidobacterium longum culture using Dogo hot spring water
락토바실러스 플란타룸(Lactobacillus plantarum) 대신에 비피도박테리움 롱검(Bifidobacterium longum) 균주를 사용한 것을 제외하고는 제조예 1과 동일한 조건으로 배양하여 비피도박테리움 롱검 배양물을 수득하였다A Bifidobacterium longum culture was obtained by culturing under the same conditions as in Preparation Example 1, except that the Bifidobacterium longum strain was used instead of Lactobacillus plantarum.
제조예 3: 도고온천수+한약재 복합 추출물을 이용한 락토바실러스 플란타룸 배양물Preparation Example 3: Lactobacillus plantarum culture using Dogo hot spring water + herbal medicine composite extract
MRS Broth 액체배지 70㎖, 도고온천수 30㎖로 혼합된 혼합배지 대신에 MRS Broth 액체배지 70㎖, 도고온천수 27㎖, 한약재 복합 추출물 3㎖가 혼합된 혼합배지를 사용한 것을 제외하고는 제조예 1과 동일한 조건에서 락토바실러스 플란타룸 배양물을 수득하였다. 여기서 한약재 복합 추출물은 제조예 A의 목단피 추출물, 제조예 B의 계조축 추출물, 제조예 C의 연교 추출물을 1:1:1의 부피비로 혼합한 것이다.Except for using a mixed medium in which 70 ml of MRS Broth liquid medium, 27 ml of Dogo hot spring water, and 3 ml of herbal medicine complex extract were used instead of a mixed medium mixed with 70 ml of MRS Broth liquid medium and 30 ml of Dogo hot spring water, Preparation Example 1 and Lactobacillus plantarum cultures were obtained under the same conditions. Here, the herbal medicine composite extract is a mixture of the Moutan bark extract of Preparation Example A, the Gyejochuk extract of Preparation Example B, and the Yeongyo extract of Preparation Example C at a volume ratio of 1: 1: 1.
제조예 4: 도고온천수+한약재 복합 추출물을 이용한 비피도박테리움 롱검 배양물Preparation Example 4: Bifidobacterium longum culture using Dogo hot spring water + herbal medicine complex extract
락토바실러스 플란타룸(Lactobacillus plantarum) 대신에 비피도박테리움 롱검(Bifidobacterium longum) 균주를 사용한 것을 제외하고는 제조예 3과 동일한 조건으로 배양하여 비피도박테리움 롱검 배양물을 수득하였다.A Bifidobacterium longum culture was obtained by culturing under the same conditions as in Preparation Example 3, except that the Bifidobacterium longum strain was used instead of Lactobacillus plantarum.
비교제조예 1: 도고온천수를 이용한 락토바실러스 플란타룸 균체 제거 배양물Comparative Preparation Example 1: Lactobacillus plantarum cell removal culture using Dogo hot spring water
발효 후 배양물을 호모게나이저로 처리하여 균체를 파쇄하는 대신에, 배양물을 원심분리하여 균체를 제거한 여액을 수득한 것을 제외하고는 제조예 1과 동일한 방법으로 배양물을 제조하였다.After fermentation, instead of treating the culture with a homogenizer to disrupt the cells, the culture was prepared in the same manner as in Preparation Example 1, except that the culture was centrifuged to obtain a filtrate from which the cells were removed.
비교제조예 2: 도고온천수를 이용한 비피도박테리움 롱검 균체 제거 배양물Comparative Preparation Example 2: Bifidobacterium longum cell removal culture using Dogo hot spring water
발효 후 배양물을 호모게나이저로 처리하여 균체를 파쇄하는 대신에, 배양물을 원심분리하여 균체를 제거한 여액을 수득한 것을 제외하고는 제조예 2와 동일한 방법으로 배양물을 제조하였다.After fermentation, instead of treating the culture with a homogenizer to disrupt the cells, the culture was prepared in the same manner as in Preparation Example 2, except that the culture was centrifuged to obtain a filtrate from which the cells were removed.
비교제조예 3: 도고온천수+한약재 복합 추출물을 이용한 락토바실러스 플란타룸 균체 제거 배양물Comparative Preparation Example 3: Lactobacillus plantarum cell removal culture using Dogo hot spring water + herbal medicine composite extract
발효 후 배양물을 호모게나이저로 처리하여 균체를 파쇄하는 대신에, 배양물을 원심분리하여 균체를 제거한 여액을 수득한 것을 제외하고는 제조예 3과 동일한 방법으로 배양물을 제조하였다.After fermentation, instead of treating the culture with a homogenizer to disrupt the cells, the culture was prepared in the same manner as in Preparation Example 3, except that the culture was centrifuged to obtain a filtrate from which the cells were removed.
비교제조예 4: 도고온천수+한약재 복합 추출물을 이용한 비피도박테리움 균체 제거 롱검 배양물Comparative Preparation Example 4: Removal of Bifidobacterium Cells Longum Culture Using Dogo Hot Spring Water + Herbal Medicine Complex Extract
락토바실러스 플란타룸(Lactobacillus plantarum) 대신에 비피도박테리움 롱검(Bifidobacterium longum) 균주를 사용한 것을 제외하고는 제조예 4와 동일한 조건으로 배양하여 비피도박테리움 롱검 배양물을 수득하였다.A Bifidobacterium longum culture was obtained by culturing under the same conditions as in Preparation Example 4, except that the Bifidobacterium longum strain was used instead of Lactobacillus plantarum .
실시예 1: 도고온천수를 이용한 혼합 배양물Example 1: Mixed culture using Dogo hot spring water
제조예 1의 락토바실러스 플란타룸 배양물과 제조예 2의 비피도박테리움 롱검 배양물을 1:1의 부피비로 혼합하여 혼합 배양물을 제조하였다.A mixed culture was prepared by mixing the Lactobacillus plantarum culture of Preparation Example 1 and the Bifidobacterium longum culture of Preparation Example 2 at a volume ratio of 1:1.
실시예 2: 도고온천수 + 복합 한약재 이용한 혼합 배양물Example 2: Mixed culture using Dogo hot spring water + complex herbal medicine
제조예 3의 락토바실러스 플란타룸 배양물과 제조예 4의 비피도박테리움 롱검 배양물을 1:1의 부피비로 혼합하여 혼합 배양물을 제조하였다.A mixed culture was prepared by mixing the Lactobacillus plantarum culture of Preparation Example 3 and the Bifidobacterium longum culture of Preparation Example 4 at a volume ratio of 1:1.
비교예 1: 아산온천수를 이용한 혼합 배양물Comparative Example 1: Mixed culture using Asan hot spring water
도고온천수 대신에 아산온천수를 사용한 것을 제외하고는 실시예 1과 동일한 조건으로 혼합 배양물을 제조하였다.A mixed culture was prepared under the same conditions as in Example 1, except that Asan hot spring water was used instead of Dogo hot spring water.
비교예 2: 아산온천수 + 복합 한약재 이용한 혼합 배양물Comparative Example 2: Mixed culture using Asan hot spring water + composite herbal medicine
도고온천수 대신에 아산온천수를 사용한 것을 제외하고는 실시예 1과 동일한 조건으로 혼합 배양물을 제조하였다.A mixed culture was prepared under the same conditions as in Example 1, except that Asan hot spring water was used instead of Dogo hot spring water.
비교예 3: 온양온천수를 이용한 혼합 배양물Comparative Example 3: Mixed culture using Onyang hot spring water
도고온천수 대신에 온양온천수를 사용한 것을 제외하고는 실시예 1과 동일한 조건으로 혼합 배양물을 제조하였다.A mixed culture was prepared under the same conditions as in Example 1, except that Onyang hot spring water was used instead of Dogo hot spring water.
비교예 4: 온양온천수 + 복합 한약재 이용한 혼합 배양물Comparative Example 4: Onyang hot spring water + mixed culture using complex herbal medicine
도고온천수 대신에 온양온천수를 사용한 것을 제외하고는 실시예 1과 동일한 조건으로 혼합 배양물을 제조하였다.A mixed culture was prepared under the same conditions as in Example 1, except that Onyang hot spring water was used instead of Dogo hot spring water.
비교예 5: 도고온천수를 이용한 균체 제거 혼합 배양물Comparative Example 5: Cell removal mixed culture using Dogo hot spring water
비교제조예 1의 락토바실러스 플란타룸 균체 제거 배양물과 비교제조예 2의 비피도박테리움 롱검 균체 제거 배양물을 1:1의 부피비로 혼합하여 혼합 배양물을 제조하였다.A mixed culture was prepared by mixing the Lactobacillus plantarum cell removal culture of Comparative Preparation Example 1 and the Bifidobacterium longum cell removal culture of Comparative Preparation Example 2 at a volume ratio of 1:1.
비교예 6: 도고온천수+복합 한약재 이용한 균체 제거 혼합 배양물Comparative Example 6: Cell removal mixed culture using Dogo hot spring water + complex herbal medicine
비교제조예 3의 락토바실러스 플란타룸 균체 제거 배양물과 비교제조예 4의 비피도박테리움 롱검 균체 제거 배양물을 1:1의 부피비로 혼합하여 혼합 배양물을 제조하였다.A mixed culture was prepared by mixing the Lactobacillus plantarum cell removal culture of Comparative Preparation Example 3 and the Bifidobacterium longum cell removal culture of Comparative Preparation Example 4 at a volume ratio of 1:1.
비교예 7: 도고온천수+ 목단피를 이용한 혼합 배양물Comparative Example 7: Mixed culture using Dogo hot spring water + Moutan skin
복합 한약재 추출물 대신에 제조예 A의 목단피 추출물을 단독으로 사용한 것을 제외하고는 실시예 2와 동일한 조건으로 혼합 배양물을 제조하였다.A mixed culture was prepared under the same conditions as in Example 2, except that the mudanpi extract of Preparation Example A was used alone instead of the composite herbal medicine extract.
비교예 8: 도고온천수+ 계조축을 이용한 혼합 배양물Comparative Example 8: Mixed culture using Dogo hot spring water + gradation axis
복합 한약재 추출물 대신에 제조예 B의 계조축 추출물을 단독으로 사용한 것을 제외하고는 실시예 2와 동일한 조건으로 혼합 배양물을 제조하였다.A mixed culture was prepared under the same conditions as in Example 2, except that the Gyejo axis extract of Preparation Example B was used alone instead of the composite herbal extract.
비교예 9: 도고온천수+ 연교를 이용한 혼합 배양물Comparative Example 9: Mixed culture using Dogo hot spring water + Yeongyo
복합 한약재 추출물 대신에 제조예 C의 연교 추출물을 단독으로 사용한 것을 제외하고는 실시예 2와 동일한 조건으로 혼합 배양물을 제조하였다.A mixed culture was prepared under the same conditions as in Example 2, except for using the Yeongyo extract of Preparation Example C alone instead of the composite herbal extract.
비교예 10: 도고온천수+ 목단피/계조축을 이용한 혼합 배양물Comparative Example 10: Mixed culture using Dogo hot spring water + Moutan bark / Gyejo axis
복합 한약재 추출물 대신에 제조예 A의 목단피 추출물과 제조예 B의 계조축 추출물을 1:1의 부피비로 혼합한 추출물을 사용한 것을 제외하고는 실시예 2와 동일한 조건으로 혼합 배양물을 제조하였다.A mixed culture was prepared under the same conditions as in Example 2, except that an extract obtained by mixing the extract of Moutan bark of Preparation Example A and the extract of Gyejo axis of Preparation Example B at a volume ratio of 1: 1 was used instead of the composite herbal extract.
비교예 11: 도고온천수+ 목단피/연교를 이용한 혼합 배양물Comparative Example 11: Mixed culture using Dogo hot spring water + Mudanpi / Yeongyo
복합 한약재 추출물 대신에 제조예 A의 목단피 추출물과 제조예 C의 연교 추출물을 1:1의 부피비로 혼합한 추출물을 사용한 것을 제외하고는 실시예 2와 동일한 조건으로 혼합 배양물을 제조하였다.A mixed culture was prepared under the same conditions as in Example 2, except that an extract obtained by mixing the extract of Mokdanpi of Preparation Example A and the extract of Yeongyo of Preparation Example C at a volume ratio of 1: 1 instead of the composite herbal extract was used.
비교예 12: 도고온천수+ 계조축/연교를 이용한 혼합 배양물Comparative Example 12: Mixed culture using Dogo hot spring water + gradation axis / year bridge
복합 한약재 추출물 대신에 제조예 B의 연교 추출물과 제조예 C의 연교 추출물을 1:1의 부피비로 혼합한 추출물을 사용한 것을 제외하고는 실시예 2와 동일한 조건으로 혼합 배양물을 제조하였다.A mixed culture was prepared under the same conditions as in Example 2, except that an extract obtained by mixing the extract of Yeongyo of Preparation Example B and the extract of Preparation Example C of Yeongyo of Preparation Example C at a volume ratio of 1: 1 instead of the composite herbal extract was used.
비교예 13: 도고온천수+ 복합 한약재를 이용한 단독 배양물Comparative Example 13: Single culture using Dogo hot spring water + complex herbal medicine
제조예 3에 따라 제조된 락토바실러스 플란타룸 단독 배양물을 사용하였다.A single culture of Lactobacillus plantarum prepared according to Preparation Example 3 was used.
비교예 14: 도고온천수+ 복합 한약재를 이용한 단독 배양물Comparative Example 14: Single culture using Dogo hot spring water + complex herbal medicine
제조예 4에 따라 제조된 비피도박테리움 롱검 단독 배양물을 사용하였다.A single culture of Bifidobacterium longum prepared according to Preparation Example 4 was used.
상기 제조예 1 내지 4, 비교제조예 1 내지 4, 실시예 1, 2 및 비교예 1 내지 12의 배양물 제조 조건을 아래의 표 1 및 표 2에 정리하였다.Culture preparation conditions of Preparation Examples 1 to 4, Comparative Preparation Examples 1 to 4, Examples 1 and 2, and Comparative Examples 1 to 12 are summarized in Tables 1 and 2 below.
(제조예 A,B,C)3 types complex
(Production Examples A, B, C)
(제조예 A,B,C)3 types complex
(Production Examples A, B, C)
(제조예 A,B,C)3 types complex
(Production Examples A, B, C)
(제조예 A,B,C)3 types complex
(Production Examples A, B, C)
(제조예 A,B,C)3 types complex
(Production Examples A, B, C)
(제조예 A,B,C)3 types complex
(Production Examples A, B, C)
(제조예 A,B,C)3 types complex
(Production Examples A, B, C)
(제조예 A,B,C)3 types complex
(Production Examples A, B, C)
(제조예 A:목단피)(Production Example A: Moutan Skin)
(제조예 B:계조축)(Production example B: gradation axis)
(제조예 C:연교)(Manufacture Example C: Yeongyo)
(제조예 A,B:목단피,계조축)(Manufacturing example A, B: Mokdan skin, gradation axis)
(제조예 A,C:목단피,연교)(Manufacturing Examples A, C: Moutan skin, Yeongyo)
(제조예 B,C:계조축,연교)(Manufacturing example B, C: gradation axis, year bridge)
(락토바실러스 플란타룸)(Lactobacillus plantarum)
(제조예 A,B,C)3 types complex
(Production Examples A, B, C)
(비피도박테리움 롱검)(Bifidobacterium longum)
(제조예 A,B,C)3 types complex
(Production Examples A, B, C)
참고로, 아산 지역에 분포하는 3대 온천수인 실시예에서 배지 성분으로 사용된 도고온천수와 비교예에서 사용된 아산온천수 및 온양온천수의 미네랄 성분 및 함량을 비교한 결과를 아래의 표 3에 나타내었다. 표 3의 결과는 “충남지역 온천수를 이용한 피부개선 화장품 개발”과 관련되어 공지된 과제 보고서를 인용한 것이다.For reference, the results of comparing the mineral components and contents of Dogo hot spring water used as a medium component in Examples, which are the three major hot spring waters distributed in the Asan region, and Asan hot spring water and Onyang hot spring water used in Comparative Examples are shown in Table 3 below. . The results in Table 3 are quoted from a known project report related to "development of skin-improving cosmetics using hot spring water in Chungcheongnam-do."
[실험예][Experimental example]
모든 통계 분석은 SPSS 버전 18.0(IBM, Chicago, IL, USA)을 사용하여 수행되었다. Duncan의 post-hoc test를 이용한 일원 분산 분석(one-way ANOVA)을 사용하여 실험군 간의 평균값의 차이(p <0.05)를 결정하였다. 각각의 실험데이터는 평균 ± 표준 편차(SD)로 표시하였다.All statistical analyzes were performed using SPSS version 18.0 (IBM, Chicago, IL, USA). A one-way ANOVA with Duncan's post-hoc test was used to determine the difference (p <0.05) in the mean value between the experimental groups. Data from each experiment were expressed as mean ± standard deviation (SD).
실험예 1: 세포독성 분석Experimental Example 1: Cytotoxicity assay
세포 독성은 MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide)환원 방법을 이용하여 측정하였다. 배양된 HaCaT 세포를 DMEM 배지에 잘 혼합한 후 1x105 cells/mL로 조정한 다음, 24-well 배양판에 준비된 세포를 1 mL씩 첨가한 후 3일간 배양하였다. 세포가 80% 정도 성장했을 때 우태아 혈청과 항생제를 첨가하지 않은 배지에 농도별로 실시예 1, 2 및 비교예 1 내지 4의 시료(0, 25, 50, 100, 300, 400, 500, 1000 ㎍/㎖)를 처리한 후, 24시간 더 배양을 하고 배양이 끝난 세포의 생존율을 MTT 환원 방법을 이용하여 측정하였다.Cytotoxicity was measured using the MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) reduction method. The cultured HaCaT cells were mixed well in DMEM medium, adjusted to 1x10 5 cells/mL, and then 1 mL of each prepared cell was added to a 24-well culture plate and cultured for 3 days. Samples of Examples 1 and 2 and Comparative Examples 1 to 4 (0, 25, 50, 100, 300, 400, 500, 1000 [mu]g/ml), the cells were further cultured for 24 hours, and the viability of the cultured cells was measured using the MTT reduction method.
각 well에 MTT 용액(5 mg/㎖)을 성장배지 부피의 1/10 가량 가한 후, 다시 37 ℃에서 4시간 더 배양하였다. 이후, MTT를 환원시켜 생성된 포르마잔(formazan)이 손실되지 않도록 조심하며 배지를 제거하고, 남아 있는 배지를 완전히 제거하기 위해 실온에서 30분간 방치한 후 DMSO를 이용하여 시료를 용해시킨 다음 570 nm에서 흡광도를 측정하였다. 세포 생존율은 하기 식 1에 따라 계산한 후, 그 결과를 표 4에 나타내었다.After adding about 1/10 of the volume of the growth medium to each well, the MTT solution (5 mg/ml) was further incubated at 37 °C for 4 hours. Thereafter, the medium was removed while being careful not to lose the formazan produced by reducing MTT, and after leaving the medium at room temperature for 30 minutes to completely remove the remaining medium, the sample was dissolved using DMSO and then 570 nm The absorbance was measured at. Cell viability was calculated according to Equation 1 below, and the results are shown in Table 4.
[식 1][Equation 1]
세포 생존율 (%) = [시료처리군의 흡광도/대조군의 흡광도] x 100 Cell viability (%) = [absorbance of sample treatment group/absorbance of control group] x 100
이에 따르면, 본 발명의 실시예 1 및 2에 따라 배양물 뿐만 아니라 비교예 1 내지 4의 배양물 역시 인간 피부에 안전하게 사용될 수 있음을 확인하였다. 비교예 5 내지 12의 배양물은 실시예 1, 2 또는 다른 비교예의 성분에 포함되므로 별도의 세포독성은 실시하지 않았다.According to this, it was confirmed that not only the cultures according to Examples 1 and 2 of the present invention, but also the cultures of Comparative Examples 1 to 4 can be safely used on human skin. Since the cultures of Comparative Examples 5 to 12 are included in the components of Examples 1 and 2 or other Comparative Examples, separate cytotoxicity was not performed.
실험예 2: MMP-1 합성 저해 효과 분석Experimental Example 2: MMP-1 synthesis inhibitory effect analysis
CCD-986sk를 1.5X105 cells/㎖의 농도로 35 mm dish에서 약 80% confluency에 도달할 때까지 배양하였다. 그리고 원래의 배지를 제거한 후 PBS로 세척하여 배지 내 serum 성분을 제거한 다음, 필터를 장착한 UV 광원기(Coralife, 35W, UV)를 이용하여 UVA(6. 3J/㎠)를 24시간 동안 조사하였다. UVA 조사 후 FBS를 첨가하지 않은 DMEM 배지에 본 발명의 실시예 또는 비교예의 시료를 10 및 100 ㎍/㎖의 농도별로 각각 투여한 후 24시간 동안 배양하였다. 이와 같이 배양한 배지를 96 well plate에 분주하고 4 ℃ 에서 하룻밤 동안 반응시켰다. UVA 조사에 의해 유도되는 MMP-1 발현량 측정은 Dunsmore 등이 사용한 방법을 이용하여 실시하였다.CCD-986sk was cultured in a 35 mm dish at a concentration of 1.5X10 5 cells/ml until reaching about 80% confluency. After removing the original medium, washing with PBS to remove the serum component in the medium, UVA (6.3J/cm2) was irradiated for 24 hours using a UV light source (Coralife, 35W, UV) equipped with a filter. . After UVA irradiation, the samples of Examples or Comparative Examples of the present invention were administered to each concentration of 10 and 100 μg/ml in a DMEM medium without FBS, and cultured for 24 hours. The cultured medium was dispensed into a 96 well plate and reacted overnight at 4 °C. MMP-1 expression level induced by UVA irradiation was measured using the method used by Dunsmore et al.
먼저, 상기 배지를 TBS(phosphate bufferdsaline + 0.05% Tween20)로 3회 세척한 후, 3% PBS로 37 ℃에서 1시간 동안 blocking하였다. 이후, 1차 항체 (monoclonal anti-MMP-1 antibody)를 blocking buffer로 1 : 3000의 부피비로 희석한 용액을 가하고 37 ℃에서 90분간 반응시켰다. 이후, PBS로 세척한 다음 2차 항체(alkaline phosphatase conjugated Goat anti-mouse IgG)를 blocking buffer로 1 : 3,000의 부피비로 희석한 용액을 첨가하고 37 ℃에서 90분간 반응시켰다. 이후, PBS로 세척한 다음 alkaline phosphatase 기질용액(1 ㎎/㎖, p-mitrophenylphosphate in diethanolamine buffer)을 첨가하여 실온에서 30분간 반응시킨 후, 3N NaOH로 반응을 중지시켰다. 다음으로, microplate reader를 이용하여 405 ㎚에서 흡광도를 측정하여 그 결과를 아래의 표 5에 나타내었다. First, the medium was washed three times with TBS (phosphate bufferedsaline + 0.05% Tween20), and then blocked with 3% PBS at 37 °C for 1 hour. Thereafter, a solution diluted with a blocking buffer of a primary antibody (monoclonal anti-MMP-1 antibody) at a volume ratio of 1:3000 was added and reacted at 37° C. for 90 minutes. Thereafter, after washing with PBS, a solution in which a secondary antibody (alkaline phosphatase conjugated Goat anti-mouse IgG) was diluted with a blocking buffer at a volume ratio of 1:3,000 was added and reacted at 37° C. for 90 minutes. Thereafter, after washing with PBS, alkaline phosphatase substrate solution (1 mg/ml, p-mitrophenylphosphate in diethanolamine buffer) was added, followed by reaction at room temperature for 30 minutes, and then the reaction was stopped with 3N NaOH. Next, absorbance was measured at 405 nm using a microplate reader, and the results are shown in Table 5 below.
이에 따르면, 발효 균주 2종을 사용한 혼합 배양물과 배양물 내 3종의 복합 한약재를 포함시킨 실시예 2의 배양물이 MMP-1 단백질의 합성 저해 효과가 다른 실험군에 비해 매우 높게 측정되었고, 3종 복합 한약재가 아닌 1종 또는 2종 한약재를 배지에 포함시킨 경우에도 MMP-1 단백질의 합성 저해 효과가 한약재를 제외시킨 실시예 1과 비교하여 큰 차이를 나타내지 않았다. 또한, 3종 복합 한약재를 포함하면서 아산 또는 온양온천수를 포함하는 비교예 2와 비교예 4 또한 MMP-1 단백질의 합성 저해 효과가 우수하였으나 실시예 2에 비해서는 상대적으로 낮은 효과를 나타내었다.According to this, the mixed culture using two fermented strains and the culture of Example 2 including three kinds of complex herbal medicines in the culture were measured to have a very high inhibitory effect on the synthesis of MMP-1 protein compared to other experimental groups, and 3 Even when one or two kinds of herbal medicines other than species complex herbal medicines were included in the medium, the synthesis inhibitory effect of MMP-1 protein did not show a significant difference compared to Example 1 in which herbal medicines were excluded. In addition, Comparative Example 2 and Comparative Example 4 including Asan or Onyang hot spring water including three kinds of herbal medicines also showed excellent inhibitory effect on the synthesis of MMP-1 protein, but showed a relatively low effect compared to Example 2.
또한, 배양물에서 균체를 제거한 비교예 5 및 6의 배양물의 경우에는 균체를 포함하는 실시예 1 및 2에 비하여 MMP-1 단백질의 합성 저해 효과가 낮게 측정되었으며, 발효 균주를 1종만 사용한 경우에는 콜라겐 분해효소인 MMP-1 단백질의 합성 저해 효과가 가장 낮아 주름 개선에 효과적일 것으로 보인다.In addition, in the case of the cultures of Comparative Examples 5 and 6 in which the cells were removed from the culture, the synthesis inhibitory effect of the MMP-1 protein was lower than that of Examples 1 and 2 containing the cells, and when only one fermentation strain was used, It seems to be effective in improving wrinkles as it has the lowest effect of inhibiting the synthesis of MMP-1 protein, a collagen degrading enzyme.
실험예 3: 콜라겐 합성 촉진 효과 분석Experimental Example 3: Collagen synthesis promotion effect analysis
실시예 및 비교예의 화장료 조성물에 대한 피부주름 개선효능을 확인하기 위해, 피부의 탄력을 유지하는 단백질 콜라겐의 생성량을 측정하였다. 섬유아세포를 48 well plate에 1X104 cells/well의 밀도로 분주하고, 10% FBS를 함유한 DMEM 배지에서 24시간 배양한 후에, 실시예 또는 비교예의 시료를 50 및 100 ㎍/㎖로 첨가하고 무혈청 배지에서 24시간 추가로 배양하였다. 배양 후, 각 웰의 상층액을 모아 procollagen type I C-peptide EIA kit(MK101, Takara, Japan)을 이용하여 프로콜라겐(procollagen) 타입 I C-펩타이드(PICP) 양을 측정하여 ng/㎖ 환산하였으며, 이에 의해 합성된 콜라겐 양을 측정하여 그 결과를 표 6에 나타내었다.In order to confirm the skin wrinkle improvement effect of the cosmetic compositions of Examples and Comparative Examples, the amount of protein collagen produced to maintain skin elasticity was measured. Fibroblasts were dispensed at a density of 1X10 4 cells/well in a 48 well plate, cultured for 24 hours in DMEM medium containing 10% FBS, and samples of Examples or Comparative Examples were added at 50 and 100 μg/ml, and no Incubated for an additional 24 hours in serum medium. After incubation, the supernatant of each well was collected and the amount of procollagen type I C-peptide (PICP) was measured using the procollagen type I C-peptide EIA kit (MK101, Takara, Japan) and converted into ng/ml. , The amount of collagen synthesized thereby was measured, and the results are shown in Table 6.
이에 따르면, 본 발명의 실시예 2에 따라 제조된 배양물은 무처리군 및 비교예들에 비하여 콜라겐의 생성 촉진 효과가 매우 우수함을 확인하였다. 이에 반해, 1종의 균주를 이용한 배양물이거나 3종 복합 한약재를 사용하지 않고 배양한 배양물인 경우 실시예 2에 비해 상대적으로 낮은 콜라겐 생성능을 나타내는 것으로 확인되었다. 또한, 3종 복합 한약재를 포함하면서 도고온천수가 아닌 아산온천수를 포함하는 비교예 2, 온양온천수를 포함하는 비교예 4의 경우 콜라겐 생성능이 다른 비교예들에 비하여 높은 수준을 나타내었으나 실시예 2에 비해서는 상대적으로 낮은 콜라겐 생성능을 나타내었다.According to this, it was confirmed that the culture prepared according to Example 2 of the present invention has a very excellent collagen production promoting effect compared to the untreated group and comparative examples. On the other hand, it was confirmed that a culture using one strain or a culture cultured without using three kinds of complex herbal medicines exhibited a relatively low collagen production ability compared to Example 2. In addition, in the case of Comparative Example 2 containing Asan hot spring water, not Dogo hot spring water, and Comparative Example 4 containing Onyang hot spring water, including three kinds of composite herbal medicines, the collagen production ability was higher than that of other comparative examples, but in Example 2 In comparison, it showed a relatively low collagen production ability.
실험예 4: 티로시나아제 저해 활성 분석Experimental Example 4: Analysis of tyrosinase inhibitory activity
실시예 및 비교예의 배양물에 대하여 티로시나아제 억제능을 Yagi 등(1986)의 방법에 의하여 측정하였다. 멜라닌은 표피 기저층에 존재하며, 멜라닌 합성은 melanocyte의 세포 내 멜라노솜(melasnosome)에서 티로시나아제에 의해 조절되고, 따라서 티로시나아제 활성을 억제하면 멜라닌 합성과 색소 침착을 줄일 수 있다. 시험관에 pH 6.8의 1.15M sodium phosphate buffer 0.5 ㎖에 10 mM L-DOPA을 녹인 기질액 0.2 ㎖ 및 시료용액 0.1 ㎖를 넣은 혼합액에 110 Unit/㎖ mushroom tyrosinase 0.2 ㎖를 첨가하였다. 이후 25℃에서 2분간 반응시키고 반응액 중에 생성된 DOPA chrome을 microplate reader를 이용하여 490 nm에서 흡광도를 측정하였다. 티로시나아제 저해 활성은 시료용액의 첨가군과 무첨가군의 흡광도 감소율로 나타내었으며, 그 결과를 아래의 표 7에 나타내었다.The tyrosinase inhibitory ability of the cultures of Examples and Comparative Examples was measured by the method of Yagi et al. (1986). Melanin exists in the basal layer of the epidermis, and melanin synthesis is regulated by tyrosinase in melanocyte intracellular melanocytes. Therefore, inhibiting tyrosinase activity can reduce melanin synthesis and pigmentation. 0.2 ml of 110 Unit/ml mushroom tyrosinase was added to a mixture containing 0.2 ml of a substrate solution in which 10 mM L-DOPA was dissolved in 0.5 ml of 1.15M sodium phosphate buffer at pH 6.8 and 0.1 ml of a sample solution in a test tube. After reacting at 25 ° C. for 2 minutes, the absorbance of DOPA chrome generated in the reaction solution was measured at 490 nm using a microplate reader. The tyrosinase inhibitory activity was expressed as the rate of decrease in absorbance of the sample solution added and non-added groups, and the results are shown in Table 7 below.
이에 따르면, 본 발명의 실시예 2의 배양물이 티로시나아제 저해 활성이 가장 높은 것으로 나타났으며, 3종 복합 한약재를 포함하면서 도고온천수가 아닌 아산온천수를 포함하는 비교예 2, 온양온천수를 포함하는 비교예 4의 경우 티로시나아제 저해 활성이 다른 비교예들에 비하여 높은 수준을 나타내었으나 실시예 2에 비해서는 상대적으로 낮은 수준으로 측정되었다. 이에 반해, 발효 균주를 1종만 사용하거나 2종 이하의 한약재를 사용한 경우에는 상대적으로 티로시나아제 저해 활성이 낮게 측정되었다.According to this, the culture of Example 2 of the present invention was found to have the highest tyrosinase inhibitory activity, and Comparative Example 2 containing Asan hot spring water, not Dogo hot spring water, including three kinds of complex herbal medicines, including Onyang hot spring water In the case of Comparative Example 4, the tyrosinase inhibitory activity was higher than that of other Comparative Examples, but was measured at a relatively low level compared to Example 2. On the other hand, when only one fermentation strain was used or two or less herbal medicinal materials were used, the tyrosinase inhibitory activity was measured to be relatively low.
실험예 5: 멜라닌 생성 억제능 분석Experimental Example 5: Analysis of melanin production inhibitory ability
마우스 유래 melanocyte인 B16F1 세포는 멜라닌(melanin)을 생성하며, 멜라닌은 표피 기저층에 존재하는 melanocyte내의 소기관인 melanosome에서 생합성되고 이는 가시광선 영역대의 흡광도를 측정함으로써 생성량을 비교할 수 있다. B16F1 세포 접종 후 3일간 시료를 처리하고 배지를 제거한 다음 세포를 PBS로 세척하고, 각 well당 1 ㎖의 1 N NaOH를 첨가한 후 교반하여 세포막을 융해함으로써 멜라닌 성분을 녹여 나오게 하여, 가시광선 영역대 중 가장 파장이 짧은 푸른색 가시광선영역인 400 ㎚에서 흡광도를 측정함으로써 생성된 멜라닌의 양을 측정하였다. Mouse-derived melanocyte B16F1 cells produce melanin, and melanin is biosynthesized in the melanosome, an organelle within the melanocyte present in the basal layer of the epidermis, and the amount of melanin produced can be compared by measuring the absorbance in the visible light range. After inoculation of B16F1 cells, the sample was treated for 3 days, the medium was removed, the cells were washed with PBS, 1 ml of 1 N NaOH was added to each well, and the melanin component was dissolved by stirring to melt the cell membrane, and the visible light range The amount of melanin produced was measured by measuring the absorbance at 400 nm, which is the shortest wavelength in the blue visible ray region.
상기 멜라닌 양은 단위 세포수당(106 cell)의 흡광도로 나타내는 방법으로 측정하였으며, 대조군(무처리군)에 대한 상대적인 멜라닌 생성량을 저해율(%)로 계산하고 결과를 표 8에 정리하였다.The amount of melanin was measured by a method of expressing absorbance per unit cell number (10 6 cell), and the relative amount of melanin production with respect to the control group (untreated group) was calculated as an inhibition rate (%), and the results are summarized in Table 8.
이에 따르면, 실시예 2의 배양물이 멜라닌 생성 억제능이 가장 우수한 것으로 나타났으며, 3종 복합 한약재를 포함하면서 도고온천수가 아닌 아산온천수를 포함하는 비교예 2, 온양온천수를 포함하는 비교예 4의 경우 멜라닌 생성 억제능이 다른 비교예들에 비하여 높은 수준을 나타내었으나 실시예 2에 비해서는 상대적으로 낮게 측정되었다. 또한, 발효 균주를 1종만 사용하거나, 2종 이하 한약재를 사용한 경우에는 멜라닌 생성 억제능이 크게 저하되는 것으로 나타났다.According to this, the culture of Example 2 was found to have the best melanin production inhibitory ability, and in Comparative Example 2 containing Asan hot spring water, not Dogo hot spring water, including three complex herbal medicines, and Comparative Example 4 containing Onyang hot spring water In this case, the melanin production inhibitory ability showed a high level compared to other comparative examples, but was measured relatively low compared to Example 2. In addition, it was found that the ability to inhibit melanogenesis was greatly reduced when only one fermented strain was used or two or less herbal medicines were used.
본 발명을 적용하기에 적합한 화장료 조성물의 제제예를 제시한다.Formulation examples of cosmetic compositions suitable for application of the present invention are presented.
제제예 1: 화장수Formulation Example 1: Lotion
실시예 2의 화장료 조성물을 이용한 화장수의 제제예는 하기 표 9와 같다.Formulation examples of lotion using the cosmetic composition of Example 2 are shown in Table 9 below.
제제예 2: 로션Formulation Example 2: Lotion
실시예 2의 화장료 조성물을 이용한 로션의 제제예는 하기 표 10과 같다.Formulation examples of lotions using the cosmetic composition of Example 2 are shown in Table 10 below.
제제예 3: BB 크림Formulation Example 3: BB Cream
실시예 2의 화장료 조성물을 이용한 BB 크림의 제제예는 하기 표 11과 같다.Formulation examples of BB cream using the cosmetic composition of Example 2 are shown in Table 11 below.
제제예 4: 에센스Formulation Example 4: Essence
실시예 2의 화장료 조성물을 이용한 에센스의 제제예는 하기 표 12와 같다.Formulation examples of essence using the cosmetic composition of Example 2 are shown in Table 12 below.
제제예 5: 마스크 팩용 유액Formulation Example 5: Emulsion for mask pack
실시예 2의 화장료 조성물을 이용한 마스크 팩용 유액의 제제예는 하기 표 13과 같다.Formulation examples of emulsions for mask packs using the cosmetic composition of Example 2 are shown in Table 13 below.
이상, 본 발명의 실시예들에 대하여 설명하였으나, 해당 기술 분야에서 통상의 지식을 가진 자라면 특허청구범위에 기재된 본 발명의 사상으로부터 벗어나지 않는 범위 내에서, 구성 요소의 부가, 변경, 삭제 또는 추가 등에 의해 본 발명을 다양하게 수정 및 변경시킬 수 있을 것이며, 이 또한 본 발명의 권리범위 내에 포함된다고 할 것이다.Although the embodiments of the present invention have been described above, those skilled in the art can add, change, delete, or add components within the scope not departing from the spirit of the present invention described in the claims. The present invention can be variously modified and changed by the like, and this will also be said to be included within the scope of the present invention.
Claims (9)
도고온천수를 포함하는 배지에서 배양된 비피도박테리움(Bifidobacterium) 속 균주를 포함하는 배양물;을 유효성분으로 포함하는 화장료 조성물.Cultures containing strains of the genus Lactobacillus cultured in a medium containing Dogo hot spring water; and
Bifidobacterium cultured in a medium containing Dogo hot spring water ( Bifidobacterium ) A culture containing a genus strain; A cosmetic composition containing as an active ingredient.
상기 도고온천수를 포함하는 배지는 목단피 추출물, 계조축 추출물 및 연교 추출물 중에서 선택된 1종 이상을 포함하는 한약재 추출물을 추가로 포함하는 것을 특징으로 하는 화장료 조성물.According to claim 1,
The medium containing the Dogo hot spring water is a cosmetic composition, characterized in that it further comprises a herbal extract containing at least one selected from the mudanpi extract, gyejochuk extract and yeongyo extract.
상기 한약재 추출물은 물, 탄소수 1-4의 알코올, 또는 이들의 혼합용매에 의해 추출된 것을 특징으로 하는 화장료 조성물.According to claim 2,
The herbal extract is a cosmetic composition, characterized in that extracted by water, alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
상기 도고온천수를 포함하는 배지는 상기 도고온천수를 10 내지 40 %(v/v) 포함하는 것을 특징으로 하는 화장료 조성물.According to claim 2,
The medium containing the Dogo hot spring water is a cosmetic composition, characterized in that it contains 10 to 40% (v / v) of the Dogo hot spring water.
상기 도고온천수를 포함하는 배지는 상기 한약재 추출물을 1 내지 5 %(v/v) 포함하고, 상기 한약재 추출물은 고형분 함량이 10 내지 20%(w/v)인 것을 특징으로 하는 화장료 조성물.According to claim 2,
The medium containing the Dogo hot spring water contains 1 to 5% (v / v) of the herbal extract, and the herbal extract has a solid content of 10 to 20% (w / v) Cosmetic composition.
상기 도고온천수는 칼슘(Ca) 55 내지 65 mg/L, 나트륨(Na) 25 내지 35 mg/L, 실리콘(Si) 10 내지 20 mg/L, 리튬(Li) 0.001 내지 0.05 mg/L 및 스트론튬(Sr) 1.0 내지 2.0 mg/L를 포함하는 것을 특징으로 하는 화장료 조성물.According to claim 1,
The Dogo hot spring water contains 55 to 65 mg/L of calcium (Ca), 25 to 35 mg/L of sodium (Na), 10 to 20 mg/L of silicon (Si), 0.001 to 0.05 mg/L of lithium (Li) and strontium ( Sr) A cosmetic composition comprising 1.0 to 2.0 mg/L.
상기 락토바실러스(Lactobacillus) 속 균주는 락토바실러스 플란타룸( Lactobacillus plantarum), 락토바실러스 루테리(Lactobacillus reuteri), 락토바실러스 하비넨시스(Lactobacillus harbinensis), 락토바실러스 카세이(Lactobacillus casei), 락토바실러스 사케이(Lactobacillus sakei), 락토바실러스 브레비스(Lactobacillus brevis), 락토바실러스 펜토서스(Lactobacillus pentosus), 락토바실러스 퍼멘텀(Lactobacillus fermentum), 락토바실러스 애시도필러스(Lactobacillus acidophilus) 및 락토바실러스 람노서스(Lactobacillus rhamnosus) 중에서 선택된 어느 하나인 것을 특징으로 하는 화장료 조성물.According to claim 1,
The strains of the genus Lactobacillus include Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus harbinensis, Lactobacillus casei, Lactobacillus sake ( Among Lactobacillus sakei), Lactobacillus brevis, Lactobacillus pentosus, Lactobacillus fermentum, Lactobacillus acidophilus and Lactobacillus rhamnosus A cosmetic composition, characterized in that the selected one.
상기 비피도박테리움(Bifidobacterium) 속 균주는 비피도박테리움 롱검(Bifidobacterium longum), 비피도박테리움 브레베(Bifidobacterium breve), 비피도박테리움 락티스(Bifidobacterium lactis), 및 비피도박테리움 비피덤(Bifidobacterium bifidum) 중에서 선택된 어느 하나인 것을 특징으로 하는 화장료 조성물.According to claim 1,
The Bifidobacterium genus strains include Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium lactis, and Bifidobacterium bifidum. (Bifidobacterium bifidum) A cosmetic composition, characterized in that any one selected from.
상기 화장료 조성물은 피부 미백 또는 주름 개선용인 것을 특징으로 하는 화장료 조성물.According to claim 1,
The cosmetic composition is a cosmetic composition, characterized in that for skin whitening or wrinkle improvement.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210104376A KR102659125B1 (en) | 2021-08-09 | 2021-08-09 | Cosmetic composition comprising probiotics cultivatied using dogo hot spring water |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210104376A KR102659125B1 (en) | 2021-08-09 | 2021-08-09 | Cosmetic composition comprising probiotics cultivatied using dogo hot spring water |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20230022514A true KR20230022514A (en) | 2023-02-16 |
KR102659125B1 KR102659125B1 (en) | 2024-04-23 |
Family
ID=85326102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210104376A KR102659125B1 (en) | 2021-08-09 | 2021-08-09 | Cosmetic composition comprising probiotics cultivatied using dogo hot spring water |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102659125B1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101256883B1 (en) * | 2010-08-16 | 2013-04-22 | 청운대학교산학협력단 | Cosmetic composition |
KR101492003B1 (en) * | 2013-04-29 | 2015-02-23 | 주식회사한국야쿠르트 | Probiotics of Lactobacillus plantarum HY7714 for skin wrinkle inhibitory and moisurizing effects and use of thereof as skin anti-wrinkle or moisturizing products |
KR101896942B1 (en) | 2017-02-24 | 2018-09-10 | 주식회사 콧데 | Composition for Cushion Type Foundation Comprising Culture Medium of Houttuynia Cordata Extract |
KR101975031B1 (en) * | 2019-04-02 | 2019-05-07 | (주)에이투젠 | Novel Bifidobacterium longum ATG-F5, and cosmetics composition comprising thereof |
KR20190055552A (en) * | 2017-11-15 | 2019-05-23 | 한국식품연구원 | Lactobacillus plantarum WiKim0060 having skin whitening and skin moisturizing activities and composition for comprising the same |
KR20210064818A (en) | 2019-11-26 | 2021-06-03 | (주) 에이텍 | Cosmetic composition containing lactic acid bacteria fermentation of chrysanthemum and magnolia extracted with YU SEONG hot spring water |
-
2021
- 2021-08-09 KR KR1020210104376A patent/KR102659125B1/en active IP Right Grant
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101256883B1 (en) * | 2010-08-16 | 2013-04-22 | 청운대학교산학협력단 | Cosmetic composition |
KR101492003B1 (en) * | 2013-04-29 | 2015-02-23 | 주식회사한국야쿠르트 | Probiotics of Lactobacillus plantarum HY7714 for skin wrinkle inhibitory and moisurizing effects and use of thereof as skin anti-wrinkle or moisturizing products |
KR101896942B1 (en) | 2017-02-24 | 2018-09-10 | 주식회사 콧데 | Composition for Cushion Type Foundation Comprising Culture Medium of Houttuynia Cordata Extract |
KR20190055552A (en) * | 2017-11-15 | 2019-05-23 | 한국식품연구원 | Lactobacillus plantarum WiKim0060 having skin whitening and skin moisturizing activities and composition for comprising the same |
KR101975031B1 (en) * | 2019-04-02 | 2019-05-07 | (주)에이투젠 | Novel Bifidobacterium longum ATG-F5, and cosmetics composition comprising thereof |
KR20210064818A (en) | 2019-11-26 | 2021-06-03 | (주) 에이텍 | Cosmetic composition containing lactic acid bacteria fermentation of chrysanthemum and magnolia extracted with YU SEONG hot spring water |
Also Published As
Publication number | Publication date |
---|---|
KR102659125B1 (en) | 2024-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102145447B1 (en) | Cosmetic compositions containing fermented extract of Hippophae rhamnoides L | |
KR100755427B1 (en) | Cosmetic composition comprising green tea seed oil for enhancing skin elasticity | |
KR101800161B1 (en) | Wheat seed extract showing potent inhibiting effect on skin aging, the preparation thereof and the compostion comprising the same | |
KR100715485B1 (en) | Cosmetic composition comprising the root extract of nymphaea tetragona having skin whitening and anti-aging activity | |
KR101229045B1 (en) | Extracting method of nelumbo nucifera flower, leaf, stem, root, seed and cosmetic composition for anti-wrinkle containing extracts thereby | |
KR101243219B1 (en) | Skin whitening and anti-wrinkle composition comprising a fermented plant extract in Ulleung island | |
KR20200138870A (en) | Composition for preventing or improving skin aging comprising an extract of rhodiola sachalinesis fermented by bovista plumbea | |
KR100865071B1 (en) | Composition comprising the saururus chinensis extract or compound isolated therefrom for skin whitening | |
KR100535875B1 (en) | Cosmetic composition comprising the extract of complex herb showing skin anti-aging and whitening effect | |
KR100888753B1 (en) | Composition comprising an extract of Cornus kousa or the compounds isolated therefrom having anti-aging and anti-wrinkle activity | |
JP2021024805A (en) | External preparation for skin | |
KR102251306B1 (en) | Cosmetic compositions containing Lactobacillus plantarum extract | |
KR20120085369A (en) | skin-whitening, anti-bacterial and anti-inflammatory composition comprising a fermented juice of jujube and grape | |
KR20120036011A (en) | Composition comprising a leaf extract of isatis tinctoria l. showing skin whitening and anti-wrinkle activity | |
KR102632084B1 (en) | Cosmetic composition for anti-oxidation, skin whitening, and improving of skin wrinkle containing Sanguisorba officinalis extract | |
KR102087904B1 (en) | Cosmetic compositions containing bifida ferment lysate | |
KR102659125B1 (en) | Cosmetic composition comprising probiotics cultivatied using dogo hot spring water | |
KR102107490B1 (en) | Cosmetic composition containing Narcissus extract | |
KR101541842B1 (en) | Skin composition comprising the extract of fermented chestnut bur showing skin whitening and anti-aging or anti-inflammatory activity | |
KR100829831B1 (en) | A skin whitening compositions comprising natural plant extract | |
KR102659128B1 (en) | Cosmetic composition comprising dogo hot spring water | |
KR102618301B1 (en) | Cosmetic composition comprising probiotics culture | |
KR100756669B1 (en) | Cosmetic composition comprising an extract of Persicae fructus having whitening activities | |
KR101230588B1 (en) | Cosmetics Composite | |
KR101873244B1 (en) | Skin composition comprising the sprouting seed extract of Schisandra chinensis for anti-wrinkle or anti-inflammatory activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |